

Bibliografia

- 1 Abbott NJ, Patabendige AA, Dolman DE, et al. *Structure and function of the blood-brain barrier*. *Neurobiol Dis* 2010;37:13-25.
- 2 Abernethy DR, Greenblatt DJ, Shader RI. *Imipramine and desipramine disposition in the elderly*. *J Pharmacol Exp Ther* 1985;232:183-8.
- 3 Adam K, Oswald I. *Effects of lormetazepam and of flurazepam on sleep*. *Br J Clin Pharmacol* 1984;17:531-8.
- 4 Adamiak U, Kaldonska M, Klodowska-Duda G, et al. *Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease*. *Clin Neuropharmacol* 2010;33:135-41.
- 5 Addington D. *Best practices: improving quality of care for patients with first-episode psychosis*. *Psychiatr Serv* 2009;60:1164-6.
- 6 Adli M, Baethge C, Heinz A, et al. *Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed?* *Eur Arch Psychiatry Clin Neurosci* 2005;55:387-400.
- 7 Aichhorn W, Marksteiner J, Walch T, et al. *Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations*. *Int Clin Psychopharmacol* 2006;21:81-5.
- 8 Aichhorn W, Weiss U, Marksteiner J, et al. *Influence of age and gender on risperidone plasma concentrations*. *J Psychopharmacol* 2005;19:395-401.
- 9 Aichhorn W, Whitworth AB, Weiss ME, et al. *Second-generation antipsychotics: Is there evidence for sex differences in pharmacokinetic and adverse effect profiles?* *Drug Saf* 2006;29:587-98.
- 10 Åkerblad AC, Bengtsson F, Ekselius L, et al. *Effects of an educational compliance enhancement programme and therapeutic drug monitoring on treatment adherence in depressed patients managed by general practitioners*. *Int Clin Psychopharmacol* 2003;18:347-54.
- 11 Åkerblad AC, Bengtsson F, Holgersson M, et al. *Identification of primary care patients at risk of nonadherence to antidepressant treatment*. *Patient Prefer Adherence* 2008;2:379-86.
- 12 Aklillu E, Kalow W, Endrenyi L, et al. *CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine*. *Pharmacogenet Genomics* 2007;17:989-93.
- 13 Akutsu T, Kobayashi K, Sakurada K, et al. *Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation*. *Drug Metab Dispos* 2007;35:72-8.
- 14 Albers LJ, Ozdemir V, Marder SR, et al. *Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy*. *J Clin Psychopharmacol* 2005;25:170-4.
- 15 Alderman J, Wolkow R, Fogel IM. *Drug concentration monitoring with tolerability and efficacy assessments during open-label, long-term sertraline treatment of children and adolescents*. *J Child Adolesc Psychopharmacol* 2006;16:117-29.
- 16 Allen MH, Hirschfeld RM, Wozniak PJ, et al. *Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania*. *Am J Psychiatry* 2006;163:272-5.
- 17 Allqvist A, Miura J, Bertilsson L, et al. *Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers*. *Eur J Clin Pharmacol* 2007;63:173-9.
- 18 Altamura AC, Moro AR, Percudani M. *Clinical pharmacokinetics of fluoxetine*. *Clin Pharmacokinet* 1994;26:201-14.
- 19 Althaus M, Retzow A, Castell JV, et al. *In vitro identification of the cytochrome P450 isoform responsible for the metabolism of alpha-dihydroergocryptine*. *Xenobiotica* 2000;30:1033-45.
- 20 Aman MG, Vinks AA, Remmerie B, et al. *Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopment disorders*. *Clin Therap* 2007;29:1476-86.
- 21 Anderson D, Reed S, Lintemoot J, et al. *A first look at duloxetine (Cymbalta) in a post-mortem laboratory*. *J Analyt Toxicology* 2006;30:576-9.
- 22 Anderson GD. *Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach*. *Clin Pharmacokinet* 2005;44:989-1008.
- 23 Anderson IM, Ferrier IN, Baldwin RC, et al. *Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines*. *J Psychopharmacol* 2008;22:343-96.
- 24 Aoki FY, Sitar DS. *Clinical pharmacokinetics of amantadine hydrochloride*. *Clin Pharmacokinet* 1988;14:35-51.
- 25 Aps JK, Martens LC. *Review: The physiology of saliva and transfer of drugs into saliva*. *Forensic Sci Int* 2005;150:119-31.
- 26 Arakawa R, Ito H, Takano A, et al. *Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia*. *Psychopharmacology (Berl)* 2008;197:229-35.
- 27 Aravagiri M, Marder SR, Yuwiler A, et al. *Distribution of fluphenazine and its metabolites in brain regions and other tissues of the rat*. *Neuropsychopharmacology* 1995;13:235-47.
- 28 Aravagiri M, Teper Y, Marder SR. *Pharmacokinetics and tissue distribution of olanzapine in rats*. *Biopharm Drug Dispos* 1999;20:369-77.
- 29 Aravagiri M, Yuwiler A, Marder SR. *Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat*. *Psychopharmacology* 1998;139:356-63.
- 30 Åsberg M, Cronholm B, Sjöqvist F, et al. *Correlation of subjective side effects with plasma concentrations of nortriptyline*. *Br Med J* 1970;5726:18-21.
- 31 Åsberg M, Crönholm B, Sjöqvist F, et al. *Relationship between plasma level and therapeutic effect of nortriptyline*. *Br Med J* 1971;3:331-4.
- 32 Bachmann CJ, Haberhausen M, Heinzel-Gutenbrunner M, et al. *Large intraindividual variability of olanzapine serum*

- concentrations in adolescent patients. *Ther Drug Monit* 2008;30:108-12.
- 33 Bachmann CJ, Rieger-Gies A, Heinzl-Gutenbrunner M, et al. *Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia*. *Ther Drug Monit* 2008;30:462-6.
- 34 Bachus R, Bickel U, Thomsen T, et al. *The O-demethylation of the antimentia drug galanthamine is catalysed by cytochrome P450 2D6*. *Pharmacogenetics* 1999;9:661-8.
- 35 Backman JT, Olkkola KT, Ojala M, et al. *Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin*. *Epilepsia* 1996;37:253-7.
- 36 Bagli M, Höflich G, Rao ML, et al. *Bioequivalence and absolute bioavailability of oblong and coated levomepromazine tablets in CYP2D6 phenotyped subjects*. *Int J Clin Pharmacol Ther* 1995;33:646-52.
- 37 Baker GB, Urlichuk LJ, McKenna KF, et al. *Metabolism of monoamine oxidase inhibitors*. *Cell Mol Neurobiol* 1999;19:411-26.
- 38 Bakken GV, Rudberg I, Christensen H, et al. *Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5*. *Drug Metab Dispos* 2009;37:254-8.
- 39 Balant LP, Balant-Gorgia AE, Eisele R, et al. *Clinical and pharmacokinetic evaluation of zuclopenthixol acetate in Viscoleo*. *Pharmacopsychiatry* 1989;22:250-4.
- 40 Balant-Gorgia AE, Eisele R, Aeschlimann JM, et al. *Plasma flupentixol concentrations and clinical response in acute schizophrenia*. *Ther Drug Monit* 1985;7:411-4.
- 41 Barbhaiya RH, Shukla UA, Pfeffer M, et al. *Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses*. *Eur J Clin Pharmacol* 1994;46:41-7.
- 42 Bareggi SR, Bianchi L, Cavallaro R, et al. *Citalopram concentrations and response in obsessive-compulsive disorder. Preliminary results*. *CNS Drugs* 2004;18:329-35.
- 43 Barski OA, Tipparaju SM, Bhatnagar A. *The aldo-keto reductase superfamily and its role in drug metabolism and detoxification*. *Drug Metab Rev* 2008;40:553-624.
- 44 Baruzzi A, Bordo B, Bossi L, et al. *Plasma levels of di-nopropylacetate and clonazepam in epileptic patients*. *Int J Clin Pharmacol Biopharm* 1977;15:403-8.
- 45 Bates DW, Gawande AA. *Improving safety with information technology*. *N Engl J Med* 2003;348:2526-34.
- 46 Bauer M, Whybrow PC, Angst J, et al. *World Federation of Societies Biological Psychiatry Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder*. *World J Biol Psychiatry* 2002;3:5-43.
- 47 Bauer S, David Rudd G, Mylius V, et al. *Lacosamide intoxication in attempted suicide*. *Epilepsy Behav* 2010;17:549-51.
- 48 Baumann P. *Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors*. *Clin Pharmacokinet* 1996;31:444-69.
- 49 Baumann P, Barbe R, Vabre-Bogdalova A, et al. *Epileptiform seizure after sertraline treatment in an adolescent experiencing obsessive-compulsive disorder and presenting a rare pharmacogenetic status*. *J Clin Psychopharmacol* 2006;26:679-81.
- 50 Baumann P, Hiemke C, Ulrich S, et al. *Le dosage plasmatique des médicaments psychotropes à des fins thérapeutiques: recommandations du groupe d'experts AGNP-TDM*. *Rev Med Suisse* 2006;2:1413-8.
- 51 Baumann P, Hiemke C, Ulrich S, et al. *The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry*. *Pharmacopsychiatry* 2004;37:243-65.
- 52 Baumann P, Ulrich S, Eckermann G, et al. *The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants*. *Dialogues Clin Neurosci* 2005;7:231-47.
- 53 Baumann P, Zullino DF, Eap CB. *Enantiomers' potential in psychopharmacology—a critical analysis with special emphasis on the antidepressant escitalopram*. *Eur Neuropsychopharmacol* 2002;12:433-44.
- 54 Bazire S. *Psychotropic Drug Directory 2010*. Aberdeen: Healthcomm UK Ltd 2011.
- 55 Beasley CM Jr, Stauffer VL, Liu-Seifert H, et al. *All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis*. *J Clin Psychopharmacol* 2007;27:252-8.
- 56 Bech P, Gex-Fabry M, Aubry JM, et al. *Olanzapine plasma level in relation to antimanic effect in the acute therapy of manic states*. *Nord J Psychiatry* 2006;60:181-2.
- 57 Becquemont L, Mouajjah S, Escaffre O, et al. *Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism*. *Drug Metab Dispos* 1999;27:1068-73.
- 58 Beedham C, Miceli JJ, Obach RS. *Ziprasidone metabolism, aldehyde oxidase, and clinical implications*. *J Clin Psychopharmacol* 2003;23:229-32.
- 59 Benedetti MS, Whomsley R, Poggesi I, et al. *Drug metabolism and pharmacokinetics*. *Drug Metab Rev* 2009;41:344-90.
- 60 Benetton SA, Fang C, Yang YO, et al. *P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine*. *Drug Metab Pharmacokinet* 2007;22:78-87.
- 61 Bengtsson F. *Therapeutic drug monitoring of psychotropic drugs. TDM "nouveau"*. *Ther Drug Monit* 2004;26:145-51.
- 62 Bennett JP Jr, Piercey MF. *Pramipexole: a new dopamine agonist for the treatment of Parkinson's disease*. *J Neurol Sci* 1999;163:25-31.
- 63 Bergemann N, Frick A, Parzer P, et al. *Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients*. *Pharmacopsychiatry* 2004;37:63-8.
- 64 Bergemann N, Kopitz J, Kress KR, et al. *Plasma amisulpride*

- levels in schizophrenia or schizoaffective disorder. *Eur Neuropsychopharmacology* 2004;14:245-50.
- 65 Bergemann N, Rommel F, Conca A. *Therapeutisches Drug-Monitoring von Psychopharmaka in der Schwangerschaft*. *J Neurol Neurochir Psychiatr* 2009;10:38-40.
- 66 Bergmann TK, Bathum L, Brøsen K. *Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6*. *Eur J Clin Pharmacol* 2001;57:123-7.
- 67 Bergstrom RF, Cerimele BJ. *Olanzapine in subjects with and without renal failure (data on file)*. Lilly Laboratory for Clinical Research. Eli Lilly and Co. 1996.
- 68 Berry D, Millington C. *Analysis of pregabalin at therapeutic concentrations in human plasma/serum by reversed-phase HPLC*. *Ther Drug Monit* 2005;27:451-6.
- 69 Bertelsen KM, Venkatakrishnan K, von Moltke LL, et al. *Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine*. *Drug Metab Dispos* 2003;31:289-93.
- 70 Berwaerts J, Cleton A, Rossenu S, et al. *A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia*. *J Psychopharmacol* 2010;24:1011-8.
- 71 Bigliani V, Mulligan RS, Acton PD, et al. *Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study*. *Psychopharmacology (Berl)* 2000;150:132-40.
- 72 Birkenhäger TK, van den Broek WW, Moleman P, et al. *Imipramine dose in relation to therapeutic plasma level: are clinical trials using imipramine as a positive control flawed?* *Psychopharmacology (Berl)* 2005;181:595-9.
- 73 Bjerkenstedt L, Flyckt L, Overø KF, et al. *Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. A double-blind comparison of three dose levels*. *Eur J Clin Pharmacol* 1985;28:553-7.
- 74 Bjørndal N, Bjerre M, Gerlach J, et al. *High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin*. *Psychopharmacology (Berl)* 1980;67:17-23.
- 75 Bockbrader HN. *Clinical pharmacokinetics of gabapentin*. *Drugs Today* 1995;31:613-9.
- 76 Bockbrader HN, Burger P, Knapp L, et al. *Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures*. *Epilepsia* 2011;52:248-57.
- 77 Bockbrader HN, Wesche D, Miller R, et al. *A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin*. *Clin Pharmacokinet* 2010;49:661-9.
- 78 Bogaards JJ, Hissink EM, Briggs M, et al. *Prediction of inter-individual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modeling*. *Eur J Pharm Sci* 2000;12:117-24.
- 79 Bomsien S, Aderjan R, Mattern R, et al. *Effect of psychotropic medication on the in vitro metabolism of buprenorphine in human cDNA-expressed cytochrome P450 enzymes*. *Eur J Clin Pharmacol* 2006;62:639-43.
- 80 Bond A, Seijas D, Dawling S, et al. *Systemic absorption and abuse liability of snorted flunitrazepam*. *Addiction* 1994;89:821-30.
- 81 Bondolfi G, Morel F, Crettol S, et al. *Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients*. *Ther Drug Monit* 2005;27:539-43.
- 82 Bont L, Bosker HA, Brus F, et al. *Torsade de pointes after pipamperone intoxication*. *Pharm World Sci* 1998;20:137.
- 83 Borgstrom L, Larsson H, Molander L. *Pharmacokinetics of parenteral and oral melperone in man*. *Eur J Clin Pharmacol* 1982;23:173-6.
- 84 Borys DJ, Setzer SC, Ling LJ, et al. *Acute fluoxetine overdose: a report of 234 cases*. *Am J Emerg Med* 1992;10:115-20.
- 85 Bosse GM, Spiller HA, Collins AM. *A fatal case of venlafaxine overdose*. *J Med Toxicol* 2008;4:18-20.
- 86 Brachtendorf L, Jetter A, Beckurts KT, et al. *Cytochrome P450 enzymes contributing to demethylation of maprotiline in man*. *Pharmacol Toxicol* 2002;90:144-9.
- 87 Brahmi N, Kouraiichi N, Abderrazek H, et al. *Clinical experience with carbamazepine overdose: relationship between serum concentration and neurological severity*. *J Clin Psychopharmacol* 2008;28:241-3.
- 88 Brandt C, Baumann P, Eckermann G, et al. *Therapeutic drug monitoring in Epileptologie und Psychiatrie [Therapeutic drug monitoring in epileptology and psychiatry]*. *Nervenarzt* 2008;79:167-74.
- 89 Bressan RA, Erlandsson K, Jones HM, et al. *Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? An in vivo quantitative [123I] epidepride SPET study of amisulpride-treated patients*. *Am J Psychiatry* 2003;160:1413-20.
- 90 Breyer-Pfaff U. *The metabolic fate of amitriptyline, nortriptyline and amitriptyline oxide in man*. *Drug Metab Rev* 2004;36:723-46.
- 91 Breyer-Pfaff U, Brinkschulte M, Rein W, et al. *Prediction and evaluation criteria in perazine therapy of acute schizophrenics pharmacokinetic data*. *Pharmacopsychiatry* 1983;16:160-5.
- 92 Breyer-Pfaff U, Nill K. *Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol*. *J Pharm Pharmacol* 2004;56:1601-6.
- 93 Brockmüller J, Kirchheiner J, Schmider J, et al. *The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment*. *Clin Pharmacol Ther* 2002;72:438-52.
- 94 Brøsen K. *Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry*. *Ther Drug Monit* 1996;18:393-6.
- 95 Brøsen K, Gram LF, Klysner R, et al. *Steady-state levels of imipramine and its metabolites: significance of dose-dependent kinetics*. *Eur J Clin Pharmacol* 1986;30:43-9.

- ⁹⁶ Brøsen K, Klysner R, Gram LF, et al. *Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism*. Eur J Clin Pharmacol 1986;30:679-84.
- ⁹⁷ Brøsen K, Naranjo CA. *Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram*. Eur Neuropsychopharmacol 2001;11:275-83.
- ⁹⁸ Bruijn JA, Moleman P, Mulder PG, et al. *A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients*. Psychopharmacology (Berl) 1996;127:231-7.
- ⁹⁹ Brünen S, Vincent DP, Baumann P, et al. *Therapeutic Drug Monitoring (TDM) for drugs used in the treatment of substance related disorders. Literature review using a TDM appropriateness rating scale*. Ther Drug Monit 2011; in press.
- ¹⁰⁰ Brunton LL, Lazo JS, Parker KL. *Goodman and Gilman's The Pharmacological Basis of Therapeutics*. 11th edn. New York: McGraw-Hill 2006.
- ¹⁰¹ Buchanan RW, Kreyenbuhl J, Kelly DL, et al. *Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements*. Schizophr Bull 2010;36:71-93.
- ¹⁰² Buckley NA, Dawson AH, Whyte IM, et al. *Greater toxicity in overdose of dothiepin than of other tricyclic antidepressants*. Lancet 1994;343:159-62.
- ¹⁰³ Burke MJ, Preskorn SH. *Therapeutic drug monitoring of antidepressants. Cost implications and relevance to clinical practice*. Clin Pharmacokinet 1999;37:147-65.
- ¹⁰⁴ Byerly MJ, Thompson A, Carmody T, et al. *Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia*. Psychiatr Serv 2007;58:844-7.
- ¹⁰⁵ Caccia S, Garattini S. *Pharmacokinetic and pharmacodynamic significance of antidepressant drug metabolites*. Pharmacol Res 1992;26:317-29.
- ¹⁰⁶ Caccia S, Pasia L, Nobili L. *New atypical antipsychotics for schizophrenia: iloperidone*. Drug Des Devel Ther 2010;4:33-48.
- ¹⁰⁷ Callaghan JT, Bergstrom RF, Ptak LR, et al. *Olanzapine. Pharmacokinetic and pharmacodynamic profile*. Clin Pharmacokinet 1999;37:177-93.
- ¹⁰⁸ Canal M, Desanti CR, Santoni JP. *A new oral formulation of tiapride (drops): pharmacokinetic profile and therapeutic applications*. Clin Drug Investig 1998;15:455-60.
- ¹⁰⁹ Canal-Raffin M, Déridet E, Titier K, et al. *Simplified ultraviolet liquid chromatographic method for determination of sertindole, dehydrosertindone and norsertindole, in human plasma*. J Chromatography B 2005;814:61-7.
- ¹¹⁰ Canal-Raffin M, Titier K, Déridet E, et al. *Myocardium distribution of sertindole and its metabolite dehydrosertindole in guinea-pigs*. Biopharm Drug Dispos 2006;27:171-9.
- ¹¹¹ Carlsson B, Olsson G, Reis M, et al. *Enantioselective analysis of citalopram and metabolites in adolescents*. Ther Drug Monit 2001;23:658-64.
- ¹¹² Castberg I, Skogvoll E, Spigset O. *Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service*. J Clin Psychiatry 2007;68:1540-5.
- ¹¹³ Castberg I, Spigset O. *Prescribing pattern and use of therapeutic drug monitoring of psychotropic medication in a psychiatric high-security unit*. Ther Drug Monit 2008;30:597-603.
- ¹¹⁴ Causon R. *Validation of chromatographic methods in biomedical analysis. Viewpoint and discussion*. J Chromatogr B Biomed Sci Appl 1997;689:175-80.
- ¹¹⁵ Cawello W, Braun M, Boekens H. *Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery*. Drug Metab Dispos 2009;37:2055-60.
- ¹¹⁶ Centerholt C, Ekblom M, Odergren T, et al. *Pharmacokinetics and sedative effects in healthy subjects and subjects with impaired liver function after continuous infusion of clome-thiazole*. Eur J Clin Pharmacol 2003;59:117-22.
- ¹¹⁷ Chakraborty BS, Midha KK, McKay G, et al. *Single dose kinetics of thioridazine and its two psychoactive metabolites in healthy humans: a dose proportionality study*. J Pharm Sci 1989;78:796-801.
- ¹¹⁸ Chan V, Morris RG, Ilett KF, et al. *Population pharmacokinetics of lamotrigine*. Ther Drug Monit 2001;23:630-5.
- ¹¹⁹ Chang YC, Lane HY, Yang KH, et al. *Optimizing early prediction for antipsychotic response in schizophrenia*. J Clin Psychopharmacol 2006;26:554-9.
- ¹²⁰ Chawarski MC, Schottenfeld RS, O'Connor PG, et al. *Plasma concentrations of buprenorphine 24 to 72 hours after dosing*. Drug Alcohol Depend 1999;55:157-63.
- ¹²¹ Chen H, Grover S, Yu L, et al. *Bioactivation of lamotrigine in vivo in rat and in vitro in human liver microsomes, hepatocytes, and epidermal keratinocytes: characterization of thioether conjugates by liquid chromatography/mass spectrometry and high field nuclear magnetic resonance spectroscopy*. Chem Res Toxicol 2010;23:159-70.
- ¹²² Chen P, Tanasijevic MJ, Schoenenberger RA, et al. *A computer-based intervention for improving the appropriateness of antiepileptic drug level monitoring*. Am J Clin Pathol 2003;119:432-8.
- ¹²³ Cheng YF, Paalzow LK, Bondesson U, et al. *Pharmacokinetics of haloperidol in psychotic patients*. Psychopharmacology (Berl) 1987;91:410-4.
- ¹²⁴ Chenu F, Batten LA, Zernig G, et al. *Comparison of pharmacokinetic profiles of brand-name and generic formulations of citalopram and venlafaxine: a crossover study*. J Clin Psychiatry 2009;70:958-66.
- ¹²⁵ Chermá MD, Löfgren UB, Almkvist G, et al. *Assessment of the prescription of antidepressant drugs in elderly nursing home patients*. J Clin Psychopharmacol 2008;28:424-31.
- ¹²⁶ Chermá MD, Reis M, Hägg S, et al. *Therapeutic drug monitoring of ziprasidone in a clinical treatment setting*. Ther Drug Monit 2008;30:682-8.
- ¹²⁷ Chetty M, Gouws E, Miller R, et al. *The use of a side effect*

- as a qualitative indicator of plasma chlorpromazine levels. *Eur Neuropsychopharmacol* 1999;9:77-82.
- 128 Choc MG, Hsuan F, Honigfeld G, et al. *Single- vs multiple-dose pharmacokinetics of clozapine in psychiatric patients*. *Pharm Res* 1990;7:347-51.
- 129 Choong E, Dobrin M, Carrupt PA, et al. *The permeability P-glycoprotein: a focus on enantioselectivity and brain distribution*. *Expert Opin Drug Metab Toxicol* 2010;6:953-65.
- 130 Ciraulo DA, Hitzemann RJ, Somoza E, et al. *Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials*. *J Clin Pharmacol* 2006;46:179-92.
- 131 Citrome L. *Paliperidone palmitate. Review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication*. *Int J Clin Pract* 2010;64:216-39.
- 132 Citrome L, Stauffer VL, Chen L, et al. *Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia*. *J Clin Psychopharmacol* 2009;29:278-83.
- 133 Collins N, Barnes TR, Shingleton-Smith A, et al. *Standards of lithium monitoring in mental health trusts in the UK*. *BMC Psychiatry* 2010;10:80.
- 134 Conca A, Schmidt E, Pastore M, et al. *Therapeutic drug monitoring in Italian psychiatry*. *Pharmacopsychiatry* 2011;44:259-62.
- 135 Contin M, Riva R, Martinelli P, et al. *Effect of meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled release in parkinsonian patients*. *Eur J Clin Pharmacol* 1998;54:303-8.
- 136 Cooper TB. *Plasma level monitoring of antipsychotic drugs*. *Clin Pharmacokinet* 1978;3:14-38.
- 137 Coppen A, Kopera H. *Workshop on the clinical pharmacology and efficacy of mianserin*. *Br J Clin Pharmacol* 1978;5:91-9S.
- 138 Correll CU, Malhotra AK, Kaushik S, et al. *Early prediction of antipsychotic response in schizophrenia*. *Am J Psychiatry* 2003;160:2063-5.
- 139 Couchman L, Morgan PE, Spencer EP, et al. *Plasma clozapine and norclozapine in patients prescribed different brands of clozapine (Clozaril, Denzapine, and Zaponex)*. *Ther Drug Monit* 2010;32:624-7.
- 140 Couchman L, Morgan PE, Spencer EP, et al. *Plasma clozapine, norclozapine, and the clozapine: norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007*. *Ther Drug Monit* 2010;32:438-47.
- 141 Coulomb F, Ducret F, Laneury JP, et al. *Pharmacokinetics of single-dose reboxetine in volunteers with renal insufficiency*. *J Clin Pharmacol* 2000;40:482-7.
- 142 Cournoyer G, De Montigny C, Ouellette J, et al. *A comparative double-blind controlled study of trimipramine and amitriptyline in major depression: lack of correlation with 5-hydroxytryptamine reuptake blockade*. *J Clin Psychopharmacol* 1987;7:385-93.
- 143 Court MH. *Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system*. *Drug Metab Rev* 2010;42:202-17.
- 144 Crettol S, Besson J, Croquette-Krokar M, et al. *Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment*. *Prog Neuropsychopharmacol Biol Psychiatry* 2008;32:1722-7.
- 145 Crettol S, Déglon JJ, Besson J, et al. *ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment*. *Clin Pharmacol Ther* 2006;80:668-81.
- 146 Crettol S, Déglon JJ, Besson J, et al. *Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment*. *Clin Pharmacol Ther* 2005;78:593-604.
- 147 Cummings J, Lefèvre G, Small G, et al. *Pharmacokinetic rationale for the rivastigmine patch*. *Neurology* 2007;69(Suppl 1):S10-3.
- 148 Dahl SG. *Active metabolites of neuroleptic drugs: possible contribution to therapeutic and toxic effects*. *Ther Drug Monit* 1982;4:33-40.
- 149 Dahl SG, Strandjord RE, Sigfusson S. *Pharmacokinetics and relative bioavailability of levomepromazine after repeated administration of tablets and syrup*. *Eur J Clin Pharmacol* 1977;11:305-10.
- 150 Darby JK, Pasta DJ, Wilson MG, et al. *Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study*. *Clin Drug Investig* 2008;28:553-64.
- 151 Daviss WB, Perel JM, Birmaher B, et al. *Steady-state clinical pharmacokinetics of bupropion extended-release in youths*. *J Am Acad Child Adolesc Psychiatry* 2006;45:1503-9.
- 152 Daviss WB, Perel JM, Brent DA, et al. *Acute antidepressant response and plasma levels of bupropion and metabolites in a pediatric-aged sample: an exploratory study*. *Ther Drug Monit* 2006;28:190-8.
- 153 Dawling S. *Monitoring of tricyclic antidepressant therapy*. *Clin Biochem* 1982;15:56-61.
- 154 de Lange EC. *Potential role of ABC transporters as a detoxification system at the blood-CSF barrier*. *Adv Drug Deliv Rev* 2004;56:1793-809.
- 155 de Leon J. *Glucuronidation enzymes, genes and psychiatry*. *Int J Neuropsychopharmacol* 2003;6:57-72.
- 156 de Leon J. *Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry. Current issues in clinical implementation*. *CNS Spectr* 2006;11(Suppl 3):8-12.
- 157 de Leon J. *The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19*. *J Clin Psychopharmacol* 2007;27:241-5.
- 158 de Leon J, Greenlee B, Barber J, et al. *Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities*. *Res Dev Disabil* 2009;30:613-69.

- ¹⁵⁹ de Leon J, Susce MT, Pan RM, et al. *A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.* Pharmacopsychiatry 2007;40:93-102.
- ¹⁶⁰ de Leon J, Susce MT, Pan RM, et al. *The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.* J Clin Psychiatry 2005;66:15-27.
- ¹⁶¹ de Leon J, Wynn G, Sandson NB. *The pharmacokinetics of paliperidone versus risperidone.* Psychosomatics 2010;51:80-8.
- ¹⁶² de Mey C, Althaus M, Ezan E, et al. *Erythromycin increases plasma concentrations of alpha-dihydroergocryptine in humans.* Clin Pharmacol Ther 2001;70:142-8.
- ¹⁶³ de Vries MH, Raghoebar M, Mathlener IS, et al. *Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects.* Ther Drug Monit 1992;14:493-8.
- ¹⁶⁴ de Wit M, Best AM, Epstein SK, et al. *Lorazepam concentrations, pharmacokinetics and pharmacodynamics in a cohort of mechanically ventilated ICU patients.* Int J Clin Pharmacol Ther 2006;44:466-73.
- ¹⁶⁵ Degen J, Wölke E, Seiberling M, et al. *Comparative study of the pharmacokinetics of amitriptyline oxide and trimipramine after single administration in healthy male probands and patients with renal failure.* Med Klin (Munich) 1993;88:129-33.
- ¹⁶⁶ Degner D, Grohmann R, Kropp S, et al. *Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP.* Pharmacopsychiatry 2004;37(Suppl 1): S39-45.
- ¹⁶⁷ Del Dotto P, Bonuccelli U. *Clinical pharmacokinetics of cabergoline.* Clin Pharmacokinet 2003;42:633-45.
- ¹⁶⁸ Deleu D, Northway MG, Hanssens Y. *Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.* Clin Pharmacokinet 2002;41:261-309.
- ¹⁶⁹ Deligiannidis KM. *Therapeutic drug monitoring in pregnant and postpartum women: recommendations for SSRIs, lamotrigine, and lithium.* J Clin Psychiatry 2010;71:649-50.
- ¹⁷⁰ Delva NJ, Hawken ER. *Preventing lithium intoxication. Guide for physicians.* Can Fam Physician 2001;47:1595-600.
- ¹⁷¹ Desta Z, Kerbusch T, Soukhova N, et al. *Identification and characterization of human cytochrome P450 isoforms interacting with pimozide.* J Pharmacol Exp Ther 1998;285:428-37.
- ¹⁷² Deuschle M, Härtter S, Hiemke C, et al. *Doxepin and its metabolites in plasma and cerebrospinal fluid in depressed patients.* Psychopharmacology (Berl) 1997;131:19-22.
- ¹⁷³ DeVane CL, Boulton DW, Miller LF, et al. *Pharmacokinetics of trazodone and its major metabolite m-chlorophenylpiperazine in plasma and brain of rats.* Int J Neuropsychopharmacol 1999;2:17-23.
- ¹⁷⁴ DeVane CL, Stowe ZN, Donovan JL, et al. *Therapeutic drug monitoring of psychoactive drugs during pregnancy in the genomic era: challenges and opportunities.* J Psychopharmacol 2006;20(Suppl):54-9.
- ¹⁷⁵ Diaz FJ, de Leon J, Josiassen RC, et al. *Plasma clozapine concentration coefficients of variation in a long-term study.* Schizophr Res 2005;72:131-5.
- ¹⁷⁶ Diaz FJ, Santoro V, Spina E, et al. *Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables.* Pharmacopsychiatry 2008;41:81-91.
- ¹⁷⁷ Dingemans J, Jorga K, Zürcher G, et al. *Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects.* Eur J Clin Pharmacol 1996;50:47-55.
- ¹⁷⁸ Dockens RC, Salazar DE, Fulmor IE, et al. *Pharmacokinetics of a newly identified active metabolite of buspirone after administration of buspirone over its therapeutic dose range.* J Clin Pharmacol 2006;46:1308-12.
- ¹⁷⁹ Doose DR, Walker SA, Gisclon LG, et al. *Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug.* J Clin Pharmacol 1996;36:884-91.
- ¹⁸⁰ Doran A, Obach RS, Smith BJ, et al. *The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model.* Drug Metab Dispos 2005;33:165-74.
- ¹⁸¹ dos Santos FM, Gonçalves JC, Caminha R, et al. *Pharmacokinetic/pharmacodynamic modeling of psychomotor impairment induced by oral clonazepam in healthy volunteers.* Ther Drug Monit 2009;31:566-74.
- ¹⁸² Dunbar JL, Turncliff RZ, Hayes SC, et al. *Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence.* J Stud Alcohol Drugs 2007;68:862-70.
- ¹⁸³ Duthel F, Jacob A, Dauchy S, et al. *ABC transporters and cytochromes P450 in the human central nervous system: influence on brain pharmacokinetics and contribution to neurodegenerative disorders.* Expert Opin Drug Metab Toxicol 2010;6:1161-74.
- ¹⁸⁴ Dvorchik BH, Vesell ES. *Pharmacokinetic interpretation of data gathered during therapeutic drug monitoring.* Clin Chem 1976;22:868-78.
- ¹⁸⁵ Eagles JM, McCann I, MacLeod TN, et al. *Lithium monitoring before and after the distribution of clinical practice guidelines.* Acta Psychiatr Scand 2000;101:349-53.
- ¹⁸⁶ Eap CB, Baumann P. *Analytical methods for the quantitative determination of selective serotonin reuptake inhibitors for therapeutic drug monitoring purposes in patients.* J Chromatogr B Biomed Appl 1996;686:51-63.
- ¹⁸⁷ Eap CB, Bender S, Gastpar M, et al. *Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients.* Ther Drug Monit 2000;22:209-14.
- ¹⁸⁸ Eap CB, Bertschy G, Baumann P, et al. *High interindividual*

- variability of methadone enantiomer blood levels to dose ratios. *Arch Gen Psychiatry* 1998;55:89-90.
- ¹⁸⁹ Eap CB, Buclin T, Baumann P. *Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence*. *Clin Pharmacokin* 2002;41:1153-93.
- ¹⁹⁰ Eap CB, Finkbeiner T, Gastpar M, et al. *Replacement of R-methadone by a double dose of (R,S)-methadone in addicts: interindividual variability of the R/S ratios and evidence of adaptive changes in methadone pharmacokinetics*. *Eur J Clin Pharmacol* 1996;50:385-9.
- ¹⁹¹ Eap CB, Koeb L, Baumann P. *Determination of trimipramine and its demethylated and hydroxylated metabolites in plasma by gas chromatography-mass spectrometry*. *J Chromatogr* 1994;652:97-103.
- ¹⁹² Eap CB, Lima CA, Macciardi F, et al. *Steady state concentrations of the enantiomers of mianserin and desmethylmianserin in poor and in homozygous and heterozygous extensive metabolizers of debrisoquine*. *Ther Drug Monit* 1998;20:7-13.
- ¹⁹³ Eichelbaum M, Ingelman-Sundberg M, Evans WE. *Pharmacogenomics and individualized drug therapy*. *Annu Rev Med* 2006;57:119-37.
- ¹⁹⁴ Egberts K, Mehler-Wex C, Gerlach M. *Therapeutic drug monitoring in child and adolescent psychiatry*. *Pharmacopsychiatry* 2011;44:249-53.
- ¹⁹⁵ Eggert Hansen C, Rosted Christensen T, Elley J, et al. *Clinical pharmacokinetic studies of perphenazine*. *Br J Clin Pharmacol* 1976;3:915-23.
- ¹⁹⁶ Ellinwood EH JR, Heatherly DG, Nikaido AM, et al. *Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam and diazepam*. *Psychopharmacology* 1985;86:392-9.
- ¹⁹⁷ Ereshefsky L, Jann MW, Saklad SR, et al. *Effects of smoking on fluphenazine clearance in psychiatric inpatients*. *Biol Psychiatry* 1985;20:329-32.
- ¹⁹⁸ Evans LE, Bett JH, Cox JR, et al. *The bioavailability of oral and parenteral chlorimipramine (Anafranil)*. *Prog Neuropsychopharmacol* 1980;4:293-302.
- ¹⁹⁹ Evans WE, Relling MV. *Pharmacogenomics: translating functional genomics into rational therapeutics*. *Science* 1999;286:487-91.
- ²⁰⁰ Faber MS, Fuhr U. *Time response of cytochrome P450 1A2 activity on cessation of heavy smoking*. *Clin Pharmacol Ther* 2004;76:178-84.
- ²⁰¹ Faber MS, Jetter A, Fuhr U. *Assessment of CYP1A2 activity in clinical practice: why, how, and when?* *Basic Clin Pharmacol Toxicol* 2005;97:125-34.
- ²⁰² Faessel HM, Gibbs MA, Clarc DJ, et al. *Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers*. *J Clin Pharmacol* 2006;46:1439-48.
- ²⁰³ Faiman MD, Jensen JC, Lacoursiere RB. *Elimination kinetics of disulfiram in alcoholics after single and repeated doses*. *Clin Pharmacol Ther* 1984;36:520-6.
- ²⁰⁴ Falkai P, Wobrock T, Lieberman J, et al. *World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia*. *World J Biol Psychiatry* 2005;6:132-91.
- ²⁰⁵ Falkai P, Wobrock T, Lieberman J, et al. *World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia*. *World J Biol Psychiatry* 2006;7:5-40.
- ²⁰⁶ Fanton L, Bévalot F, Grait H, et al. *Fatal intoxication with milnacipran*. *J Forensic Leg Med* 2008;15:388-90.
- ²⁰⁷ Farde L, Nordström AL, Wiesel FA, et al. *Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine*. *Arch Gen Psychiatry* 1992;49:538-44.
- ²⁰⁸ Feng Y, Pollock BG, Coley K, et al. *Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study*. *J Clin Pharmacol* 2008;66:629-39.
- ²⁰⁹ Feng Y, Pollock BG, Ferrell RE, et al. *Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling*. *Br J Clin Pharmacol* 2006;61:558-69.
- ²¹⁰ Fenner KS, Troutman MD, Kempshall S, et al. *Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug*. *Clin Pharmacol Ther* 2009;85:173-81.
- ²¹¹ Ferrari A, Bertolotti M, Dell'Utri A, et al. *Serum time course of naltrexone and 6 β -naltrexol levels during long term treatment in drug addicts*. *Drug Alcohol Depend* 1998;52:211-20.
- ²¹² Figueroa C, Brecher M, Hamer-Maansson JE, et al. *Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release*. *Prog Neuropsychopharmacol Biol Psychiatry* 2009;33:199-204.
- ²¹³ Findling RL, Reed MD, Myers C, et al. *Paroxetine pharmacokinetics in depressed children and adolescents*. *J Am Acad Child Adolesc Psychiatry* 1999;38:952-9.
- ²¹⁴ Fitzgerald PB, Kapur S, Remington G, et al. *Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels*. *Psychopharmacology (Berl)* 2000;149:1-5.
- ²¹⁵ Flanagan RJ. *Developing an analytical toxicology service: principles and guidance*. *Toxicol Rev* 2004;23:251-63.
- ²¹⁶ Fleming J, Chetty M. *Therapeutic monitoring of valproate in psychiatry: how far have we progressed?* *Clin Neuropharmacol* 2006;29:350-60.
- ²¹⁷ Fogelman SM, Schmider J, Venkatakrishnan K, et al. *O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants*. *Neuropsychopharmacology* 1999;20:480-90.
- ²¹⁸ Fontaine R, Mercier P, Beaudry P, et al. *Bromazepam and lorazepam in generalized anxiety: a placebo-controlled study with measurement of drug plasma concentrations*. *Acta Psychiatr Scand* 1986;74:451-8.

- 219 Food and Drug Administration. *Guidance for industry: bio-analytical method validation 2001*. <http://www.fda.gov/cvm>.
- 220 Foti RS, Rock DA, Wienkers LC, et al. *Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation*. *Drug Metab Dispos* 2010;38:981-7.
- 221 Fountoulakis KN. *An update of evidence-based treatment of bipolar depression: where do we stand?* *Curr Opin Psychiatry* 2010;23:19-24.
- 222 Fric M, Pfuhlmann B, Laux G, et al. *The influence of smoking on the serum level of duloxetine*. *Pharmacopsychiatry* 2008;41:151-5.
- 223 Frieboes RM, Sonntag A, Yassouridis A, et al. *Clinical outcome after trimipramine in patients with delusional depression. A pilot study*. *Pharmacopsychiatry* 2003;36:12-7.
- 224 Friedman H, Greenblatt DJ, Peters GR, et al. *Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time*. *Clin Pharmacol Ther* 1992;52:139-50.
- 225 Fritze J, Laux G, Sofic E, et al. *Plasma moclobemide and metabolites: lack of correlation with clinical response and biogenic amines*. *Psychopharmacology (Berl)* 1989;99:252-6.
- 226 Fröscher W, Schier KR, Hoffmann M, et al. *Topiramate: a prospective study on the relationship between concentration, dosage and adverse events in epileptic patients on combination therapy*. *Epileptic Disord* 2005;7:237-48.
- 227 Fudio S, Borobia AM, Piñana E, et al. *Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram*. *Eur J Pharmacol* 2010;626:200-4.
- 228 Fukasawa T, Suzuki A, Otani K. *Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines*. *J Clin Pharm Ther* 2007;32:333-41.
- 229 Furlanut M, Montanari G, Benetello P, et al. *Steady-state serum concentrations of imipramine, its main metabolites and clinical response in primary enuresis*. *Pharmacol Res* 1989;21:561-6.
- 230 Furukori H, Kondo T, Yasui N, et al. *Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients*. *Psychopharmacology (Berl)* 1999;145:189-92.
- 231 Gaertner HJ, Golfopoulos G, Breyer-Pfaff U. *Response to Maprotiline treatment in depressive patients, relationship to urinary MHPG excretion, and plasma drug level*. *Pharmacopsychiatria* 1982;15:170-4.
- 232 Gaertner I, Gaertner HJ, Vonthein R, et al. *Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study*. *J Clin Psychopharmacol* 2001;21:305-10.
- 233 Garnock-Jones KP, Keating GM. *Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents*. *Paediatr Drugs* 2009;11:203-26.
- 234 Gelenberg AJ. *A review of the current guidelines for depression treatment*. *J Clin Psychiatry* 2010;71:e15.
- 235 Genton P, Guerrini R, Perucca E. *Tiagabine in clinical practice*. *Epilepsia* 2001;42(Suppl 3):42-5.
- 236 Gerlach M, Hünnerkopf R, Rothenhöfer S, et al. *Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders*. *Pharmacopsychiatry* 2007;40:72-6.
- 237 Gerstenberg G, Aoshima T, Fukasawa T, et al. *Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxaminic acid in Japanese depressed patients*. *Psychopharmacology (Berl)* 2003;167:443-8.
- 238 Gervasini G, Carrillo JA, Benitez J. *Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds*. *Clin Pharmacokinet* 2004;43:693-706.
- 239 Gex-Fabry M, Balant-Gorgia AE, Balant LP. *Clomipramine concentration as a predictor of delayed response: a naturalistic study*. *Eur J Clin Pharmacol* 1999;54:895-902.
- 240 Gex-Fabry M, Balant-Gorgia AE, Balant LP. *Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication*. *Ther Drug Monit* 2003;25:46-53.
- 241 Gex-Fabry M, Balant-Gorgia AE, Balant LP, et al. *Time course of clinical response to venlafaxine: relevance of plasma level and chirality*. *Eur J Clin Pharmacol* 2004;59:883-91.
- 242 Gex-Fabry M, Gervasoni N, Eap CB, et al. *Time course of response to paroxetine: influence of plasma level*. *Prog Neuropsychopharmacol Biol Psychiatry* 2007;31:892-900.
- 243 Gilles M, Deuschle M, Kellner S, et al. *Paroxetine serum concentrations in depressed patients and response to treatment*. *Pharmacopsychiatry* 2005;38:118-21.
- 244 Gillman PK. *Tricyclic antidepressant pharmacology and therapeutic drug interactions updated*. *Br J Pharmacol* 2007;151:737-48.
- 245 Glassman AH, Perel JM, Shostak M, et al. *Clinical implications of imipramine plasma levels for depressive illness*. *Arch Gen Psychiatry* 1977;34:197-204.
- 246 Glassman AH, Schildkraut JJ, Orsulak PJ, et al. *Tricyclic antidepressants, blood level measurements and clinical outcome: an APA task force report*. *Am J Psychiat* 1985;142:155-62.
- 247 Glauser TA, Pippenger CE. *Controversies in blood-level monitoring: reexamining its role in the treatment of epilepsy*. *Epilepsia* 2000;41(Suppl 8):S6-15.
- 248 Gleason MM, Egger HL, Emslie GJ, et al. *Psychopharmacological treatment for very young children: contexts and guidelines*. *J Am Acad Child Adolesc Psychiatry* 2007;46:1532-72.
- 249 Glotzbach RK, Preskorn SH. *Brain concentrations of tricyclic antidepressants: Single-dose kinetics and relationship to plasma concentrations in chronically dosed rats*. *Psychopharmacology* 1982;78:25-7.
- 250 Goeringer KE, Raymon L, Christian GD, et al. *Postmortem forensic toxicology of selective serotonin reuptake inhibitors: a review of pharmacology and report of 168 cases*. *J Forensic Sci* 2000;45:633-48.

- 251 Gomolin IH, Smith C, Jeitner TM. *Once-daily memantine: pharmacokinetic and clinical considerations*. J Am Geriatr Soc 2010;58:1812-3.
- 252 Gonzalez JP, Brogden RN. *Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence*. Drugs 1988;35:192-213.
- 253 Goodnick PJ, Dominguez RA, DeVane CL, et al. *Bupropion slow-release response in depression: diagnosis and biochemistry*. Biol Psychiatry 1998;44:629-32.
- 254 Goodwin GM; Consensus Group of the British Association for Psychopharmacology. *Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology*. J Psychopharmacol 2009;23:346-88.
- 255 Gram LF, Guentert TW, Grange S, et al. *Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study*. Clin Pharmacol Ther 1995;57:670-7.
- 256 Grandjean EM, Aubry JM. *Lithium: updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring*. CNS Drugs 2009;23:331-49.
- 257 Grasmäder K, Verwohlt PL, Kühn KU, et al. *Relationship between mirtazapine dose, plasma concentration, response, and side effects in clinical practice*. Pharmacopsychiatry 2005;38:113-7.
- 258 Grasmäder K, Verwohlt PL, Rietschel M, et al. *Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting*. Eur J Clin Pharmacol 2004;60:329-36.
- 259 Greenblatt DJ, Blaskovich PD, Nuwayser ES, et al. *Clonazepam pharmacokinetics: comparison of subcutaneous microsphere injection with multiple-dose oral administration*. J Clin Pharmacol 2005;45:1288-93.
- 260 Greenblatt DJ, Divoll M, Harmatz JS, et al. *Oxazepam kinetics: effects of age and sex*. J Pharmacol Exp Ther 1980;215:86-91.
- 261 Greenblatt DJ, Ehrenberg BL, Gunderman J, et al. *Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo*. Clin Pharmacol Ther 1989;45:356-65.
- 262 Greenblatt DJ, Friedman H, Burstein ES, et al. *Trazodone kinetics: effect of age, gender, and obesity*. Clin Pharmacol Ther 1987;42:193-200.
- 263 Greenblatt DJ, Gan L, Harmatz JS, et al. *Pharmacokinetics and pharmacodynamics of single-dose triazolam: electroencephalography compared with the Digit-Symbol Substitution Test*. Br J Clin Pharmacol 2005;60:244-8.
- 264 Greenblatt DJ, Harmatz JS, Friedman H, et al. *A large-sample study of diazepam pharmacokinetics*. Ther Drug Monit 1989;11:652-7.
- 265 Greenblatt DJ, Harmatz JS, von Moltke LL, et al. *Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo*. Clin Pharmacol Ther 1998;64:553-61.
- 266 Greenblatt DJ, Shader RI, Franke K, et al. *Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans*. J Pharm Sci 1979;68:57-63.
- 267 Greenblatt DJ, von Moltke LL, Ehrenberg BL, et al. *Kinetics and dynamics of lorazepam during and after continuous intravenous infusion*. Crit Care Med 2000;28:2750-7.
- 268 Greenblatt DJ, von Moltke LL, Harmatz JS, et al. *Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone*. J Clin Pharmacol 2003;43:414-22.
- 269 Greiner C, Hiemke C, Bader W, et al. *Determination of citalopram and escitalopram together with their active main metabolites desmethyl(es-)citalopram in human serum by column-switching high performance liquid chromatography (HPLC) and spectrophotometric detection*. J Chromatogr B Analyt Technol Biomed Life Sci 2007;848:391-4.
- 270 Grimaldi R, Perucca E, Ruberto G, et al. *Pharmacokinetic and pharmacodynamic studies following the intravenous and oral administration of the antiparkinsonian drug biperiden to normal subjects*. Eur J Clin Pharmacol 1986;29:735-7.
- 271 Grohmann R, Engel RR, Rütger E, et al. *The AMSP drug safety program: methods and global results*. Pharmacopsychiatry 2004;37(Suppl 1):S4-11.
- 272 Gründer G, Carlsson A, Wong DF. *Mechanism of new anti-psychotic medications. Occupancy is not just antagonism*. Arch Gen Psychiatry 2003;60:974-7.
- 273 Gründer G, Fellows C, Janouschek H, et al. *Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study*. Am J Psychiatry 2008;165:988-95.
- 274 Gründer G, Hiemke C, Paulzen M, et al. *Therapeutic drug concentrations of antidepressants and antipsychotics: Guidance from PET imaging*. Pharmacopsychiatry 2011;44:236-48.
- 275 Gründer G, Hippus H, Carlsson A. *The 'atypicality' of antipsychotics: a concept re-examined and re-defined*. Nat Rev Drug Discov 2009;8:197-202.
- 276 Grunze H, Vieta E, Goodwin GM. *The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania*. World J Biol Psychiatry 2009;10:85-116.
- 277 Guay DR. *Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease*. Am J Geriatr Pharmacother 2006;4:330-46.
- 278 Guberman A, Couture M, Blaschuk K, et al. *Add-on trial of clobazam in intractable adult epilepsy with plasma level correlations*. Can J Neurol Sci 1990;17:311-6.
- 279 Gunes A, Spina E, Dahl ML, et al. *ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety*. Ther Drug Monit 2008;30:628-33.
- 280 Gupta N. *Guidelines for lithium monitoring: are they ideal?* Acta Psychiatr Scand 2001;104:76-7.
- 281 Gupta RN, Dziurdzy SA. *Therapeutic monitoring of sertraline*. Clin Chem 1994;40:498-9.

- 282 Gupta SK, Shah JC, Hwang SS. *Pharmacokinetic and pharmacodynamic characterization of OROS and immediate-release amitriptyline*. Br J Clin Pharmacol 1999;48:71-8.
- 283 Guy W, editor. *ECDEU Assessment Manual for Psychopharmacology*. Rockville, MD: U.S. Department of Health, Education, and Welfare 1976.
- 284 Haberstroh J, Hampel H, Pantel J. *Optimal management of Alzheimer's disease patients: Clinical guidelines and family advice*. Neuropsychiatr Dis Treat 2010;6:243-53.
- 285 Haen E, Greiner C, Bader W, et al. *Wirkstoffkonzentrationsbestimmungen zur Therapieleitung. Ergänzung therapeutischer Referenzbereiche durch dosisbezogene Referenzbereiche*. Nervenarzt 2008;79:558-66.
- 286 Hallett C, Dean BC. *Bromazepam: acute benefit-risk assessment in general practice*. Curr Med Res Opin 1984;8:683-8.
- 287 Hammarberg A, Beck O, Eksborg S, et al. *Acamprosate determinations in plasma and cerebrospinal fluid after multiple dosing measured by liquid chromatography-mass spectrometry: a pharmacokinetic study in healthy volunteers*. Ther Drug Monit 2010;32:489-96.
- 288 Hammarberg A, Jayaram-Lindström N, Berck O, et al. *The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial*. Psychopharmacol 2009;205:53-62.
- 289 Hanley JA, McNeil BJ. *The meaning and use of the area under a receiver operating characteristic (ROC) curve*. Radiology 1982;143:29-36.
- 290 Harden CL, Trifiletti R, Kutt H. *Felbamate levels in patients with epilepsy*. Epilepsia 1996;37:280-3.
- 291 Härtter S, Dingemans J, Baier D, et al. *The role of cytochrome P450 2D6 in the metabolism of moclobemide*. Eur Neuropsychopharmacol 1996;6:225-30.
- 292 Härtter S, Hermes B, Hiemke C. *Automated determination of trimipramine and N-desmethyl-trimipramine in human plasma or serum by HPLC with on-line solid phase extraction*. J Liq Chromatogr 1995;18:3495-505.
- 293 Härtter S, Hermes B, Szegedi A, et al. *Automated determination of paroxetine and its main metabolite by column switching and on-line high-performance liquid chromatography*. Ther Drug Monit 1994;16:400-6.
- 294 Härtter S, Hiemke C. *Column switching and high-performance liquid chromatography in the analysis of amitriptyline, nortriptyline and hydroxylated metabolites in human plasma or serum*. J Chromatogr 1992;578:273-82.
- 295 Härtter S, Tybring G, Friedberg T, et al. *The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19*. Pharm Res 2002;19:1034-7.
- 296 Härtter S, Wang X, Weigmann H, et al. *Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin*. J Clin Psychopharmacol 2001;21:167-74.
- 297 Härtter S, Weigmann H, Hiemke C. *Automated determination of reboxetine by high-performance liquid chromatography with column-switching and ultraviolet detection*. J Chromatogr B Biomed Sci Appl 2000;740:135-40.
- 298 Härtter S, Wetzel H, Hiemke C. *Automated determination of fluvoxamine in plasma by column-switching high-performance liquid chromatography*. Clin Chem 1992;38:2082-6.
- 299 Hasselström J, Linnet K. *Quetiapine serum concentrations in psychiatric patients: the influence of comedication*. Ther Drug Monit 2004;26:486-91.
- 300 Hässler F, Reis O. *Pharmacotherapy of disruptive behavior in mentally retarded subjects: a review of the current literature*. Dev Disabil Res Rev 2010;16:265-72.
- 301 Haymond J, Ensom MH. *Does valproic acid warrant therapeutic drug monitoring in bipolar affective disorder?* Ther Drug Monit 2010;32:19-29.
- 302 Hazell P, Becker K, Nikkanen EA, et al. *Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder*. Atten Defic Hyperact Disord 2009;1:201-10.
- 303 Hegerl U, Bottlender R, Gallinat J, et al. *The serotonin syndrome scale: first results on validity*. Eur Arch Psychiatry Clin Neuroci 1998;248:96-103.
- 304 Heikkinen H, Saraheimo M, Antila S, et al. *Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope technique*. Eur J Clin Pharmacol 2001;56:821-6.
- 305 Heller S, Hiemke C, Stroba G, et al. *Assessment of storage and transport stability of new antidepressant and antipsychotic drugs for a nationwide TDM service*. Ther Drug Monit 2004;26:459-61.
- 306 Hendset M, Hermann M, Lunde H, et al. *Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole*. Eur J Clin Pharmacol 2007;63:1147-51.
- 307 Herman BD, Fleishaker JC, Brown MT. *Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans*. Clin Pharmacol Ther 1999;66:374-9.
- 308 Hermida J, Paz E, Tutor JC. *Clozapine and norclozapine concentrations in serum and plasma samples from schizophrenic patients*. Ther Drug Monit 2008;30:41-5.
- 309 Hesse LM, He P, Krishnaswamy S, et al. *Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes*. Pharmacogenetics 2004;14:225-38.
- 310 Hiemke C. *Clinical utility of drug measurement and pharmacokinetics. Therapeutic drug monitoring in psychiatry*. Eur J Clin Pharmacol 2008;64:159-66.
- 311 Hiemke C. *Therapeutic drug monitoring in neuropharmacology: does it hold its promises?* Eur Arch Psychiatry Clin Neurosci 2008;258(Suppl 1):21-7.
- 312 Hiemke C, Baumann P, Laux G, et al. *Therapeutisches Drug-Monitoring in der Psychiatrie. Konsensus-Leitlinie der AGNP*. Psychopharmakotherapie 2005;12:166-82.
- 313 Hiemke C, Dragicevic A, Gründer G, et al. *Therapeutic monitoring of new antipsychotic drugs*. Ther Drug Monit 2004;26:156-60.

- ³¹⁴ Hiemke C, Härtter S. *Pharmacokinetics of selective serotonin reuptake inhibitors*. *Pharmacol Ther* 2000;85:11-28.
- ³¹⁵ Higuchi H, Yoshida K, Takahashi H, et al. *Milnacipran plasma levels and antidepressant response in Japanese major depressive patients*. *Hum Psychopharmacol* 2003;18:255-9.
- ³¹⁶ Höjer J, Hulting J, Salmons H. *Fatal cardiotoxicity induced by venlafaxine overdose*. *Clin Toxicol (Phila)* 2008;46:336-7.
- ³¹⁷ Holbrook JM, Parks-Veal P, Mimbs J. *Clinical monitoring guidelines for neuroleptic and antidepressant drugs*. *Central State Hospital, Milledgeville, Georgia. Hosp Pharm* 1991;26:783-4, 787-93.
- ³¹⁸ Holzer L, Preuss U, Baumgartner L, et al. *Quetiapine in adolescents with non-affective psychotic disorders: an open-label trial*. *Pharmacopsychiatry* 2011;44:87-95.
- ³¹⁹ Hooper WD, Dickinson RG, Dunstan PR, et al. *Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant*. *Clin Exp Neurol* 1987;24:105-12.
- ³²⁰ Horadam VW, Sharp JG, Smilack JD, et al. *Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function*. *Ann Intern Med* 1981;94:454-8.
- ³²¹ Hrdina PD, Lapierre YD. *Plasma levels of maprotiline and zimelidine and their relationship to clinical response in depressed patients*. *Ther Drug Monit* 1986;8:400-6.
- ³²² Hsieh YH, Yang YH, Yeh HH, et al. *Simultaneous determination of galantamine, rivastigmine and NAP 226-90 in plasma by MEKC and its application in Alzheimer's disease*. *Electrophoresis* 2009;30:644-53.
- ³²³ Hughes J, Gill AM, Mulhearn H, et al. *Steady-state plasma concentrations of midazolam in critically ill infants and children*. *Ann Pharmacother* 1996;30:27-30.
- ³²⁴ Hui WK, Mitchell LB, Kavanagh KM, et al. *Melperone: electrophysiologic and antiarrhythmic activity in humans*. *J Cardiovasc Pharmacol* 1990;15:144-9.
- ³²⁵ Ilett KF, Blythe TH, Hackett LP, et al. *Plasma concentrations of dothiepin and its metabolites are not correlated with clinical efficacy in major depressive illness*. *Ther Drug Monit* 1993;15:351-7.
- ³²⁶ Isacson G, Holmgren P, Druid H, et al. *The utilization of antidepressants—a key issue in the prevention of suicide: an analysis of 5281 suicides in Sweden during the period 1992-1994*. *Acta Psychiatr Scand* 1997;96:94-100.
- ³²⁷ Isbister GK, Hackett LP, Dawson AH, et al. *Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity*. *Br J Clin Pharmacol* 2003;56:441-50.
- ³²⁸ Ishida M, Otani K, Kaneko S, et al. *Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine*. *Int Clin Psychopharmacol* 1995;10:143-6.
- ³²⁹ Iwersen S, Schmoldt A. *One fatal and one nonfatal intoxication with tranlycypromine. Absence of amphetamines as metabolites*. *J Anal Toxicol* 1996;20:301-4.
- ³³⁰ Jaanson P, Marandi T, Kiivet RA, et al. *Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype*. *Psychopharmacology (Berl)* 2002;162:67-73.
- ³³¹ Janis GC, Markowitz JS. *Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics*. *Clin Pharmacol Ther* 2007;81:346-53.
- ³³² Jann MW, Grimsley SR, Gray EC, et al. *Pharmacokinetics and pharmacodynamics of clozapine*. *Clin Pharmacokinet* 1993;24:161-76.
- ³³³ Jann MW, Shirley KL, Small GW. *Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors*. *Clin Pharmacokinet* 2002;41:719-39.
- ³³⁴ Jaquenoud Sirot E, Knezevic B, Morena GP, et al. *ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine*. *J Clin Psychopharmacol* 2009;29:319-26.
- ³³⁵ Jaquenoud Sirot E, van der Velden JW, Rentsch K, et al. *Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance*. *Drug Safety* 2006;29:735-68.
- ³³⁶ Jefferson JW, Pradko JF, Muir KT. *Bupropion for major depressive disorder: pharmacokinetic and formulation considerations*. *Clin Therap* 2005;27:1685-95.
- ³³⁷ Jerling M, Dahl ML, Aberg-Wistedt A, et al. *The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol*. *Clin Pharmacol Ther* 1996;59:423-8.
- ³³⁸ Ji P, Damle B, Xie J, et al. *Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects*. *J Clin Pharmacol* 2008;48:948-56.
- ³³⁹ Jimmink A, Caminada K, Hunfeld NG, et al. *Clinical toxicology of citalopram after acute intoxication with the sole drug or in combination with other drugs: overview of 26 cases*. *Ther Drug Monit* 2008;30:365-71.
- ³⁴⁰ Jin Y, Pollock BG, Frank E, et al. *The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram*. *J Clin Pharmacol* 2009;49:176-84.
- ³⁴¹ Jochemsen R, Wesselman JG, Hermans J, et al. *Pharmacokinetics of brotizolam in healthy subjects following intravenous and oral administration*. *Br J Clin Pharmacol* 1983;16(Suppl 2):285-90S.
- ³⁴² Johannessen SI, Battino D, Berry DJ, et al. *Therapeutic drug monitoring of the newer antiepileptic drugs*. *Ther Drug Monitor* 2003;25:347-63.
- ³⁴³ Johannessen SI, Tomson T. *Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?* *Clin Pharmacokinet* 2006;45:1061-75.
- ³⁴⁴ Johansson B. *A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites*. *Acta Psychiatr Scand Suppl* 1992;369:15-26.
- ³⁴⁵ Johnston JA, Fiedler-Kelly J, Glover ED, et al. *Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation*. *Nicotine Tob Res* 2001;3:131-40.
- ³⁴⁶ Jorga KM, Fotteler B, Heizmann P, et al. *Pharmacokinetics and pharmacodynamics after oral and intravenous adminis-*

- tration of tolcapone, a novel adjunct to Parkinson's disease therapy. *Eur J Clin Pharmacol* 1998;54:443-7.
- ³⁴⁷ Jorga KM, Larsen JP, Beiske A, et al. *The effect of tolcapone on the pharmacokinetics of benserazide*. *Eur J Neurol* 1999;6:211-9.
- ³⁴⁸ Jørgensen A. *Pharmacokinetic studies in volunteers of intravenous and oral cis(Z)-flupentixol and intramuscular cis (Z)-flupentixol decanoate in Viscoleo*. *Eur J Clin Pharmacol* 1980;18:355-60.
- ³⁴⁹ Jornil J, Jensen KG, Larsen F, et al. *Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator*. *Drug Metab Dispos* 2010;38:376-85.
- ³⁵⁰ Kandasamy M, Srinivas P, Subramaniam K, et al. *Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes-focus on venlafaxine and O-desmethylvenlafaxine*. *Eur J Clin Pharmacol* 2010;66:879-87.
- ³⁵¹ Kane JM, Leucht S, Carpenter D, et al. *The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary*. *J Clin Psychiatry* 2003;12(Suppl):5-19.
- ³⁵² Kaplan SA, Jack ML, Weinfeld RE, et al. *Biopharmaceutical and clinical pharmacokinetic profile of bromazepam*. *J Pharmacokinet Biopharm* 1976;4:1-16.
- ³⁵³ Kasper S, Dötsch M, Kick H, et al. *Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects*. *Eur Neuropsychopharmacol* 1993;3:13-21.
- ³⁵⁴ Katoh Y, Uchida S, Kawai M, et al. *Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients*. *Biol Pharm Bull* 2010;33:285-8.
- ³⁵⁵ Katon W, Cantrell CR, Sokol MS, et al. *Impact of antidepressant drug adherence on comorbid medication use and resource utilization*. *Arch Intern Med* 2005;165:2497-503.
- ³⁵⁶ Kaufman E, Lamster IB. *The diagnostic applications of saliva. A review*. *Crit Rev Oral Biol Med* 2002;13:197-212.
- ³⁵⁷ Kaye CM, Nicholls B. *Clinical pharmacokinetics of ropinirole*. *Clin Pharmacokinet* 2000;39:243-54.
- ³⁵⁸ Kemp DE, Ganocy SJ, Brecher M, et al. *Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression*. *J Affect Disord* 2011;130:171-9.
- ³⁵⁹ Kennedy MC. *Post mortem drug concentrations*. *Intern Med J* 2010;40:183-7.
- ³⁶⁰ Kerr BM, Thummel KE, Wurden CJ, et al. *Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation*. *Biochem Pharmacol* 1994;47:1969-79.
- ³⁶¹ Kinirons MT, O'Mahony MS. *Drug metabolism and ageing*. *Br J Clin Pharmacol* 2004;57:540-4.
- ³⁶² Kirchheiner J. *CYP2D6 phenotype prediction from genotype: which system is the best?* *Clin Pharmacol Ther* 2008;83:225-7.
- ³⁶³ Kirchheiner J, Meineke I, Müller G, et al. *Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers*. *Pharmacogenetics* 2002;12:571-80.
- ³⁶⁴ Kirchheiner J, Müller G, Meineke I, et al. *Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics*. *J Clin Psychopharmacol* 2003;23:459-66.
- ³⁶⁵ Kirchheiner J, Nickchen K, Bauer M, et al. *Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response*. *Mol Psychiatry* 2004;9:442-73.
- ³⁶⁶ Kirchherr H, Kühn-Velten WN. *Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach*. *J Chromatogr B* 2006;843:100-13.
- ³⁶⁷ Kirkton C, McIntyre IM. *Therapeutic and toxic concentrations of mirtazapine*. *J Anal Toxicol* 2006;30:687-91.
- ³⁶⁸ Kirschbaum KM, Müller MJ, Malevani J, et al. *Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects*. *World J Biol Psychiatry* 2008;9:212-8.
- ³⁶⁹ Kirschbaum KM, Müller MJ, Zernig G, et al. *Therapeutic monitoring of aripiprazole by HPLC with column-switching and spectrophotometric detection*. *Clin Chem* 2005;51:1718-21.
- ³⁷⁰ Kirschbaum KM, Uhr M, Holthoewer D, et al. *Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice*. *Neuropharmacology* 2010;59:474-9.
- ³⁷¹ Kjolbye M, Thomsen K, Rogne T, et al. *Search for a therapeutic range for serum zuclopenthixol concentrations in schizophrenic patients*. *Ther Drug Monit* 1994;16:541-7.
- ³⁷² Klamerus KJ, Maloney K, Rudolph RL, et al. *Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite*. *J Clin Pharmacol* 1992;32:716-24.
- ³⁷³ Klampfl K, Taurines R, Preuss A, et al. *Serum concentrations, therapeutic response and side effects in children and adolescents with impulsive-aggressive symptoms during risperidone therapy*. *Pharmacopsychiatry* 2010;43:58-65.
- ³⁷⁴ Klotz U. *Pharmacokinetics and drug metabolism in the elderly*. *Drug Metab Rev* 2009;41:67-76.
- ³⁷⁵ Koepp MJ, Patsalos PN, Sander JW. *Sulthiame in adults with refractory epilepsy and learning disability: an open trial*. *Epilepsy Res* 2002;50:277-82.
- ³⁷⁶ Kondo T, Otani K, Ishida M, et al. *Adverse effects of zotepine and their relationship to serum concentrations of the drug and prolactin*. *Ther Drug Monit* 1994;16:120-4.
- ³⁷⁷ Koostros-Ros JE, Van Weelden MJ, Hinrichs JW, et al. *Therapeutic drug monitoring of antidepressants and cytochrome P450 genotyping in general practice*. *J Clin Pharmacol* 2006;46:1320-7.
- ³⁷⁸ Kornhuber J, Quack G, Danysz W, et al. *Therapeutic brain*

- concentration of the NMDA receptor antagonist amantadine. *Neuropharmacology* 1995;34:713-21.
- 379 Koyama E, Chiba K, Tani M, et al. Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. *J Pharmacol Exp Ther* 1996;278:21-30.
- 380 Kozer E, Parvez S, Minassian BA, et al. How high can we go with phenytoin? *Ther Drug Monit* 2002;24:386-9.
- 381 Krska J, Corner DA. Serum drug level monitoring in affective disorders. *J Clin Pharm Ther* 1992;17:357-63.
- 382 Kugelberg FC, Druid H, Carlsson B, et al. Postmortem redistribution of the enantiomers of citalopram and its metabolites: an experimental study in rats. *J Analyt Toxicol* 2004;28:631-7.
- 383 Kuhlman JJ Jr, Levine B, Johnson RE, et al. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. *Addiction* 1998;93:549-59.
- 384 Kuss HJ, Feistenauer E. Quantitative high-performance liquid chromatographic assay for the determination of maprotiline and oxaprotiline in human plasma. *J Chromatogr* 1981;204:349-53.
- 385 Kvist EE, Al-Shurbaji A, Dahl ML, et al. Quantitative pharmacogenetics of nortriptyline: a novel approach. *Clin Pharmacokinet* 2001;40:869-77.
- 386 Lappenberg-Pelzer M. Identification and determination of opiipramol metabolites in plasma and urine. *J Anal Toxicol* 1998;22:215-9.
- 387 Lautala P, Ethell BT, Taskinen J, et al. The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases. *Drug Metab Dispos* 2000;28:1385-9.
- 388 Le Bloc'h Y, Woggon B, Weissenrieder H, et al. Routine therapeutic drug monitoring in patients treated with 10-360 mg/day citalopram. *Ther Drug Monit* 2003;25:600-8.
- 389 Lee CA, Cook JA, Reyner EL, et al. P-glycoprotein related drug interactions: clinical importance and a consideration of disease states. *Expert Opin Drug Metab Toxicol* 2010;6:603-19.
- 390 Lee SY, Kim YG, Kim HG, et al. Pharmacokinetic parameters of bromperidol in Korean subjects. *Hum Psychopharmacol* 2006;21:409-12.
- 391 Lefèvre G, Büche M, Sedek G, et al. Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patch. *J Clin Pharmacol* 2009;49:430-43.
- 392 Leucht S, Busch R, Kissling W, et al. Early prediction of antipsychotic nonresponse among patients with schizophrenia. *J Clin Psychiatry* 2007;68:352-60.
- 393 Leucht S, Steimer W, Kreuz S, et al. Doxepin plasma concentrations: is there really a therapeutic range? *J Clin Psychopharmacol* 2001;21:432-9.
- 394 LeWitt PA, Jennings D, Kelly EL, et al. Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. *Mov Disord* 2009;24:1319-24.
- 395 Licht RW, Vestergaard P, Kessing LV, et al. Psychopharmacological treatment with lithium and antiepileptic drugs: suggested guidelines from the Danish Psychiatric Association and the Child and Adolescent Psychiatric Association in Denmark. *Acta Psychiatr Scand Suppl* 2003;419:1-22.
- 396 Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med* 2005;353:1209-23.
- 397 Lind AB, Reis M, Bengtsson F, et al. Steady-state concentrations of mirtazapine, N-desmethyilmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour. *Clin Pharmacokinet* 2009;48:63-70.
- 398 Lindberger M, Luhr O, Johannessen SI, et al. Serum concentrations and effects of gabapentin and vigabatrin: observations from a dose titration study. *Ther Drug Monit* 2003;25:457-62.
- 399 Lindenmayer J. Long-acting injectable antipsychotics: focus on Olanzapine pamoate. *Neuropsychiatr Dis Treat* 2010;6:261-7.
- 400 Linder MW, Keck PE Jr. Standards of laboratory practice: antidepressant drug monitoring. *National Academy of Clinical Biochemistry*. *Clin Chem* 1998;44:1073-84.
- 401 Lingam R, Scott J. Treatment non-adherence in affective disorders. *Acta Psychiatr Scand* 2002;105:164-72.
- 402 Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. *Acta Psychiatr Scand Suppl* 1987;334:1-100.
- 403 Liu Y, Jiao J, Zhang C, et al. A simplified method to determine five cytochrome p450 probe drugs by HPLC in a single run. *Biol Pharm Bull* 2009;32:717-20.
- 404 Liu ZQ, Shu Y, Huang SL, et al. Effects of CYP2C19 genotype and CYP2C9 on fluoxetine N-demethylation in human liver microsomes. *Acta Pharmacol Sin* 2001;22:85-90.
- 405 Lobo ED, Bergstrom RF, Reddy S, et al. In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. *Clin Pharmacokinet* 2008;47:191-202.
- 406 Locatelli I, Kstelic M, Kores-Plesnicar, et al. A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode schizophrenia. *Eur J Pharm Sci* 2010;41:289-98.
- 407 Lotrich FE, Pollock BG. Aging and clinical pharmacology: implications for antidepressants. *J Clin Pharmacol* 2005;45:1106-22.
- 408 Lucek R, Dixon R. Chlordiazepoxide concentrations in saliva and plasma measured by radioimmunoassay. *Res Commun Chem Pathol Pharmacol* 1980;27:397-400.
- 409 Lundberg J, Christophersen JS, Peteresen KB, et al. *Int J Neuropsychopharmacol* 2007;10:777-85.
- 410 Lundmark J, Bengtsson F, Nordin C, et al. Therapeutic

- drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. *Acta Psychiatr Scand* 2000;101:354-9.
- ⁴¹¹ Luurila H, Olkkola KT. Pharmacokinetic-pharmacodynamic modelling of zopiclone effects on human central nervous system. *Pharmacol Toxicol* 1996;78:348-53.
- ⁴¹² Madan A, Parkinson A, Faiman MD. Identification of the human P-450 enzymes responsible for the sulfoxidation and thiono-oxidation of diethyldithiocarbamate methyl ester: role of P-450 enzymes in disulfiram bioactivation. *Alcohol Clin Exp Res* 1998;22:1212-9.
- ⁴¹³ Madsen H, Nielsen KK, Brøsen K. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms—a population study. *Br J Clin Pharmacol* 1995;39:433-9.
- ⁴¹⁴ Maguire KP, Burrows GD, Norman TR, et al. Metabolism and pharmacokinetics of dothiepin. *Br J Clin Pharmacol* 1981;12:405-9.
- ⁴¹⁵ Maguire KP, Norman TR, Burrows GD, et al. An evaluation of maprotiline intravenous kinetics and comparison of two oral doses. *Eur J Clin Pharmacol* 1980;18:249-54.
- ⁴¹⁶ Mahmood I, Sahajwalla C. Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. *Clin Pharmacokinet* 1999;36:277-87.
- ⁴¹⁷ Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. *J Clin Pharmacol* 2004;44:179-87.
- ⁴¹⁸ Mamo D, Kapur S, Keshavan M, et al. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. *Neuropsychopharmacology* 2008;33:298-304.
- ⁴¹⁹ Mamo D, Kapur S, Shammi CM, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. *Am J Psychiatry* 2004;161:818-25.
- ⁴²⁰ Mann K, Hiemke C, Lotz J, et al. Appropriateness of plasma level determinations for lithium and valproate in routine care of psychiatric inpatients with affective disorders. *J Clin Psychopharmacol* 2006;26:671-3.
- ⁴²¹ Mann K, Hiemke C, Schmidt LG, et al. Appropriateness of therapeutic drug monitoring for antidepressants in routine psychiatric inpatient care. *Ther Drug Monit* 2006;28:83-8.
- ⁴²² Markowitz J, Patrick K. Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? *J Clin Psychopharmacol* 2008;28(Suppl 2):S54-61.
- ⁴²³ Martinez C, Gatti G, Sasso E, et al. The disposition of primidone in elderly patients. *Br J Clin Pharmacol* 1990;30:607-11.
- ⁴²⁴ Mason BJ, Goodman AM, Dixon RM, et al. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. *Neuropsychopharmacology* 2002;27:596-606.
- ⁴²⁵ Mattila MA, Larni HM. Flunitrazepam: a review of its pharmacological properties and therapeutic use. *Drugs* 1980;20:353-74.
- ⁴²⁶ Mauri MC, Laini V, Boscati L, et al. Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels. *Eur Psychiatry* 2001;16:57-63.
- ⁴²⁷ Mauri MC, Volonteri LS, Colasanti A, et al. Clinical pharmacokinetics of atypical antipsychotics. A critical review of the relationship between plasma concentrations and clinical response. *Clin Pharmacokinet* 2007;46:359-88.
- ⁴²⁸ May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. *Clin Pharmacokinet* 2003;42:1023-42.
- ⁴²⁹ May TW, Korn-Merker E, Rambeck B, et al. Pharmacokinetics of sulthiame in epileptic patients. *Ther Drug Monit* 1994;16:251-7.
- ⁴³⁰ May TW, Rambeck B, Jürgens U. Serum concentrations of levetiracetam in epileptic patients: the influence of dose and co-medication. *Ther Drug Monit* 2003;25:690-9.
- ⁴³¹ May TW, Rambeck B, Jürgens U. Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication. *Ther Drug Monit* 2002;24:366-74.
- ⁴³² May TW, Rambeck B, Neb R, et al. Serum concentrations of pregabalin in patients with epilepsy: the influence of dose, age, and comedication. *Ther Drug Monit* 2007;29:789-94.
- ⁴³³ Mayo BC, Biggs SR, Chasseaud LF, et al. The metabolic fate of Sormodren (bornaprine hydrochloride) in animals and humans. *Xenobiotica* 1980;10:873-88.
- ⁴³⁴ McAlpine DE, Biernacka JM, Mrazek DA, et al. Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine. *Ther Drug Monit* 2011;33:14-20.
- ⁴³⁵ McConville BJ, Arvanitis LA, Thyrum PT, et al. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. *J Clin Psychiatry* 2000;61:252-60.
- ⁴³⁶ McKenzie ME, Roswell-Harris D. A controlled trial of prothipendyl (tolnate) in mentally subnormal patients. *Br J Psychiatry* 1966;112:95-100.
- ⁴³⁷ Medori R, Mannaert E, Gründer G. Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. *Eur Neuropsychopharmacol* 2006;16:233-40.
- ⁴³⁸ Mehler-Wex C, Kölch M, Kirchheiner J, et al. Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy. *Child Adolesc Psychiatry Ment Health* 2009;3:14.
- ⁴³⁹ Meijer WE, Bouvy ML, Heerdink ER, et al. Spontaneous lapses in dosing during chronic treatment with selective serotonin reuptake inhibitors. *Br J Psychiatry* 2001;179:519-22.
- ⁴⁴⁰ Meineke I, Kress I, Poser W, et al. Therapeutic drug monitoring and its metabolite desmethylmirtazapine by HPLC with fluorescence detection. *Ther Drug Monit* 2004;26:277-83.
- ⁴⁴¹ Meisenzahl EM, Schmitt G, Gründer G, et al. Striatal D2/D3 receptor occupancy, clinical response and side effects with

- amisulpride: an iodine-123-iodobenzamide SPET study.* Pharmacopsychiatry 2008;41:169-75.
- 442 Meyer JH. *Imaging the serotonin transporter during major depressive disorder and antidepressant treatment.* J Psychiatry Neurosci 2007;32:86-102.
- 443 Meyer JH, Wilson AA, Segrati S, et al. *Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [¹¹C]DASB positron emission tomography study.* Am J Psychiatry 2004;161:826-35.
- 444 Meyer RP, Gehlhaus M, Knoth R, et al. *Expression and function of cytochrome p450 in brain drug metabolism.* Curr Drug Metab 2007;8:297-306.
- 445 Meyer-Barner M, Meineke I, Schreeb KH, et al. *Pharmacokinetics of doxepin and desmethyldoxepin: an evaluation with the population approach.* Eur J Clin Pharmacol 2002;58:253-7.
- 446 Michelson D, Read HA, Ruff DD, et al. *CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD.* J Am Acad Child Adolesc Psychiatry 2007;46:242-51.
- 447 Mihara K, Yasui-Furukori N, Kondo T, et al. *Relationship between plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine, and its clinical effect in depressed patients.* Ther Drug Monit 2002;24:563-6.
- 448 Mimaki T. *Clinical pharmacology and therapeutic drug monitoring of zonisamide.* Ther Drug Monit 1998;20:593-7.
- 449 Miura H. *Zonisamide monotherapy with once-daily dosing in children with cryptogenic localization-related epilepsies: clinical effects and pharmacokinetic studies.* Seizure 2004;13(Suppl 1):S17-23.
- 450 Miura M, Ohkubo T. *Identification of human cytochrome P450 enzymes involved in the major metabolic pathway of fluvoxamine.* Xenobiotica 2007;37:169-79.
- 451 Moffat AC, editor. *Clarke's analysis of drugs and poisons.* London: Pharmaceutical Press 2003, pp. 1468-9.
- 452 Molden E, Lunde H, Lunder N, et al. *Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients.* Ther Drug Monit 2006;28:744-9.
- 453 Montgomery SA, McAuley R, Montgomery DB. *Relationship between mianserin plasma levels and antidepressant effect in a double-blind trial comparing a single night-time and divided daily dose regimens.* Br J Clin Pharmacol 1978;5:71-6S.
- 454 Moody DE, Chang Y, Huang W, et al. *The in vivo response of novel buprenorphine metabolites, M1 and M3, to antiretroviral inducers and inhibitors of buprenorphine metabolism.* Basic Clin Pharmacol Toxicol 2009;105:211-5.
- 455 Morris RG, Black AB, Harris AL, et al. *Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service.* Br J Clin Pharmacol 1998;46:547-51.
- 456 Morris RG, Lee MY, Cleanthous X, et al. *Long-term follow-up using a higher target range for lamotrigine monitoring.* Ther Drug Monit 2004;26:626-32.
- 457 Mrazek DA. *Psychiatric pharmacogenomic testing in clinical practice.* Dialogues Clin Neurosci 2010;12:69-76.
- 458 Müller H, Eusterschulte B, Havemann-Reinecke U, et al. *Forensische Aspekte des therapeutischen Drug-Monitorings (TDM) in der Psychiatrie.* Psychopharmakotherapie 2009;16:52-6.
- 459 Müller MJ, Dragicevic A, Fric M, et al. *Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions?* Pharmacopsychiatry 2003;36:98-104.
- 460 Müller MJ, Härter S, Köhler D, et al. *Serum levels of sulpiride enantiomers after oral treatment with racemic sulpiride in psychiatric patients: a pilot study.* Pharmacopsychiatry 2001;34:27-32.
- 461 Müller MJ, Regenbogen B, Härter S, et al. *Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia.* J Psychiat Res 2007;41:673-9.
- 462 Müller-Isberner R, Freese R, Jöckel D, et al. *Forensic psychiatric assessment and treatment in Germany. Legal framework, recent developments, and current practice.* Int J Law Psychiatry 2000;23:467-80.
- 463 Nagy CF, Kumar D, Cullen EI, et al. *Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function.* Br J Clin Pharmacol 2004;58(Suppl 1):18-24.
- 464 Naito H, Wachi M, Nishida M. *Clinical effects and plasma concentrations of long-term clonazepam monotherapy in previously untreated epileptics.* Acta Neurol Scand 1987;76:58-63.
- 465 Nakamura K, Yokoi T, Inoue K, et al. *CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes.* Pharmacogenetics 1996;6:449-57.
- 466 Nazirizadeh Y, Vogel F, Bader W, et al. *Serum concentrations of paliperidone versus risperidone and clinical effects.* Eur J Clin Pharmacol 2010;66:797-803.
- 467 Neels HM, Sierens AC, Naelaerts K, et al. *Therapeutic drug monitoring of old and newer anti-epileptic drugs.* Clin Chem Lab Med 2004;42:1228-55.
- 468 Nemoda Z, Angyal N, Tarnok Z, et al. *Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD.* Neuropharmacology 2009;57:731-3.
- 469 Nesvag R, Hendset M, Refsum H, et al. *Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication.* Acta Psychiatr Scand 2006;114:21-6.
- 470 Nikisch G, Baumann P, Oneda B, et al. *Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study.* J Psychopharmacol 2011;25:896-907.
- 471 Nikisch G, Mathé AA, Czernik A, et al. *Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid of depressive patients: relationship with 5-HIAA in CSF and clinical response.* J Clin Psychopharmacol 2004;24:283-90.

- 472 Nikolaus S, Larisch R, Beu M, et al. *In vivo measurement of D2 receptor density and affinity for 18F-(3-N-methyl)benperidol in the rat striatum with a PET system for small laboratory animals.* J Nucl Med 2003;44:618-24.
- 473 Nilsen OG, Dale O. *Single dose pharmacokinetics of trazodone in healthy subjects.* Pharmacol Toxicol 1992;71:150-3.
- 474 Nilsson MI, Meresaar U, Ånggard E. *Clinical pharmacokinetics of methadone.* Acta Anaesthesiol Scand Suppl 1982;74:66-9.
- 475 Nishikage H, Nakanishi T, Takamitsu Y, et al. *Sequential changes in the plasma concentration of risperidone following intentional overdose.* Clin Neuropharmacol 2002;25:307-9.
- 476 Nnadi CU, Malhotra AK. *Clinical and pharmacogenetic studies of iloperidone.* Per Med 2008;5:367-75.
- 477 Norman T, Chiu E, James RH, et al. *Single oral dose pharmacokinetics of tiapride in patients with Huntington's disease.* Eur J Clin Pharmacol 1987;32:583-6.
- 478 Nozawa M, Ohnuma T, Matsubara Y, et al. *The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics.* Ther Drug Monit 2008;30:35-40.
- 479 Nutt JG, Fellman JH. *Pharmacokinetics of levodopa.* Clin Neuropharmacol 1984;7:35-49.
- 480 Nyberg S, Nordström AL, Halldin C, et al. *Positron emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man.* Int Clin Psychopharmacol 1995;10(Suppl 3):81-5.
- 481 Nyholm D. *Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update.* Clin Pharmacokinet 2006;45:109-36.
- 482 Obach RS, Cox LM, Tremaine LM. *Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study.* Drug Metab Dispos 2005;33:262-70.
- 483 Öhman D, Cherma MD, Norlander B, et al. *Determination of serum reboxetine enantiomers in patients on chronic medication with racemic reboxetine.* Ther Drug Monit 2003;25:174-82.
- 484 Öhman D, Norlander B, Peterson C, et al. *Bioanalysis of racemic reboxetine and its desethylated metabolite in a therapeutic drug monitoring setting using solid phase extraction and HPLC.* Ther Drug Monit 2001;23:27-34.
- 485 Olesen OV, Linnet K. *Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes.* Drug Metab Dispos 1997;25:740-4.
- 486 Olesen OV, Linnet K. *Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine.* Br J Clin Pharmacol 2000;50:563-71.
- 487 Olesen OV, Linnet K. *Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations.* J Clin Pharmacol 2001;41:823-32.
- 488 Orsulak PJ. *Therapeutic monitoring of antidepressant drugs: current methodology and applications.* J Clin Psychiatry 1986;47(Suppl):39-52.
- 489 Orsulak PJ. *Therapeutic monitoring of antidepressant drugs: guidelines updated.* Ther Drug Monit 1989;11:497-507.
- 490 Orsulak PJ, Schildkraut JJ. *Guidelines for therapeutic monitoring of tricyclic antidepressant plasma levels.* Ther Drug Monit 1979;1:199-208.
- 491 Ostad Haji E, Tadić A, Wagner S, et al. *Association between citalopram serum levels and clinical improvement of patients with major depression.* J Clin Psychopharmacol 2011;31:281-6.
- 492 Ota T, Shinotoh H, Fukushi K, et al. *Estimation of plasma IC50 of donepezil for cerebral acetylcholinesterase inhibition in patients with Alzheimer's disease using positron emission tomography.* Clin Neuropharmacol 2010;33:74-8.
- 493 Palego L, Biondi L, Giannaccini G, et al. *Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: influence of patient-related variables.* Prog Neuro-psychopharmacol Biol Psychiatry 2002;26:473-80.
- 494 Panagiotidis G, Arthur HW, Lindh JD, et al. *Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.* Ther Drug Monit 2007;29:417-22.
- 495 Paris BL, Ogilvie BW, Scheinkoenig JA, et al. *In vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipran.* Drug Metab Dispos 2009;37:2045-54.
- 496 Park JY, Kim KA, Park PW, et al. *Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects.* Clin Pharmacol Ther 2006;79:590-9.
- 497 Park PW, Seo YH, Ahn JY, et al. *Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients.* J Clin Pharm Ther 2009;34:569-74.
- 498 Parker DR, McIntyre IM. *Case studies of post-mortem quetiapine: therapeutic or toxic concentrations?* J Analyt Toxicol 2005;29:407-12.
- 499 Patsalos PN, Berry DJ, Bourgeois BF, et al. *Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies.* Epilepsia 2008;49:1239-76.
- 500 Paz E, Bouzas L, Hermida J, et al. *Evaluation of three dosing models for the prediction of steady-state trough clozapine concentrations.* Clin Biochem 2008;41:603-6.
- 501 Pearce GA, Day RO. *Compliance with criteria necessary for effective drug concentration monitoring.* Ther Drug Monit 1990;12:250-7.
- 502 Pedersen OL, Gram LF, Kristensen CB, et al. *Overdosage of antidepressants: clinical and pharmacokinetic aspects.* Eur J Clin Pharmacol 1982;23:513-21.
- 503 Perez J, Chiron C, Musial C, et al. *Stiripentol: efficacy and tol-*

- erability in children with epilepsy. *Epilepsia* 1999;40:1618-26.
- 504 Perry PJ. *The relationship between antidepressant response and tricyclic antidepressant plasma concentrations: a retrospective analysis of the literature using logistic regression analysis.* *Clin Pharmacokinet* 1987;13:381-92.
- 505 Perry PJ. *Therapeutic drug monitoring of antipsychotics.* *Psychopharmacol Bull* 2001;35:19-29.
- 506 Perry PJ, Browne JL, Alexander B, et al. *Relationship of free nortriptyline levels to therapeutic response.* *Acta Psychiatr Scand* 1985;72:120-5.
- 507 Perry PJ, Miller DD, Arndt SV, et al. *Clozapine and nortriptyline plasma concentrations and clinical response of treatment-refractory schizophrenic patients.* *Am J Psychiatry* 1991;148:231-5.
- 508 Perry PJ, Miller DD, Arndt SV, et al. *Haloperidol dosing requirements: the contribution of smoking and nonlinear pharmacokinetics.* *J Clin Psychopharmacol* 1993;13:46-51.
- 509 Perry PJ, Sanger T, Beasley C. *Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients.* *J Clin Psychopharmacol* 1997;17:472-7.
- 510 Perry PJ, Zeilmann C, Arndt S. *Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response.* *J Clin Psychopharmacol* 1994;14:230-40.
- 511 Perucca E, Cloyd J, Critchley D, et al. *Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.* *Epilepsia* 2008;49:1123-41.
- 512 Petit P, Lonjon R, Cociglio M, et al. *Carbamazepine and its 10,11-epoxide metabolite in acute mania: clinical and pharmacokinetic correlates.* *Eur J Clin Pharmacol* 1991;41:541-6.
- 513 Peyronneau MA, Delaforge M, Riviere R, et al. *High affinity of ergopeptides for cytochromes P450 3A. Importance of their peptide moiety for P450 recognition and hydroxylation of bromocriptine.* *Eur J Biochem* 1994;223:947-56.
- 514 Pichini S, Papaseit E, Joya X, et al. *Pharmacokinetics and therapeutic drug monitoring of psychotropic drugs in pediatrics.* *Ther Drug Monit* 2009;31:283-318.
- 515 Pierce DM, Franklin RA, Harry TV, et al. *Pharmacodynamic correlates of modified absorption: studies with lormetazepam.* *Br J Clin Pharmacol* 1984;18:31-5.
- 516 Poggesi I, Benedetti MS, Whomsley R, et al. *Pharmacokinetics in special populations.* *Drug Metab Rev* 2009;41:422-54.
- 517 Potgieter GE, Groenewoud G, Jordaan PJ, et al. *Pharmacokinetics of pipamperone from three different tablet formulations.* *Arzneimittelforschung* 2002;52:430-44.
- 518 Pounder DJ, Jones GR. *Post-mortem drug redistribution. A toxicological nightmare.* *Forensic Sci Int* 1990;45:253-63.
- 519 Prakash C, Kamel A, Cui D, et al. *Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions.* *Br J Clin Pharmacol* 2000;49(Suppl 1):35-42S.
- 520 Preskorn S, Patroneva A, Silman H, et al. *Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 metabolizers.* *J Clin Psychopharmacol* 2009;29:39-43.
- 521 Preskorn SH. *CNS drug development: part I: the early period of CNS drugs.* *J Psychiatr Pract* 2010;16:334-9.
- 522 Preskorn SH. *CNS drug development: Part II: Advances from the 1960s to the 1990s.* *J Psychiatr Pract* 2010;16:413-5.
- 523 Preskorn SH. *Patients who do not respond to the "usual" dose: why Terry fell off the dose-response curve.* *J Psychiatr Pract* 2009;15:460-6.
- 524 Preskorn SH. *Practical application of therapeutic drug monitoring: a tale of two patients.* *J Psychiatr Pract* 2008;14:301-6.
- 525 Preskorn SH. *Tricyclic antidepressant plasma level monitoring: an improvement over the dose-response approach.* *J Clin Psychiatry* 1986;47(Suppl 1):24-30.
- 526 Preskorn SH, Burke MJ, Fast GA. *Therapeutic drug monitoring: principles and practice.* *Ther Drug Monit* 1993;16:611-41.
- 527 Preskorn SH, Fast GA. *Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness.* *J Clin Psychiatry* 1991;52(Suppl):23-33.
- 528 Preskorn SH, Fast GA. *Tricyclic antidepressant-induced seizures and plasma drug concentration.* *J Clin Psychiatry* 1992;53:160-2.
- 529 Preskorn SH, Fleck RJ, Schroeder DH. *Therapeutic drug monitoring of bupropion.* *Am J Psychiatry* 1990;147:1690-1.
- 530 Preskorn SH, Jerkovich GS. *Central nervous system toxicity of tricyclic antidepressants: phenomenology, course, risk factors, and role of therapeutic drug monitoring.* *J Clin Psychopharmacol* 1990;10:88-95.
- 531 Puech A, Fleurot O, Rein W. *Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol.* *Acta Psychiatr Scand* 1998;98:65-72.
- 532 Pumariega AJ, Nelson R, Rotenberg L. *Varenicline-induced mixed mood and psychotic episode in a patient with a past history of depression.* *CNS Spectr* 2008;13:511-4.
- 533 Puozzo C, Albin H, Vinçon G, et al. *Pharmacokinetics of milnacipran in liver impairment.* *Eur J Drug Metab Pharmacol* 1998;23:273-9.
- 534 Raaflaub J. *On the pharmacokinetics of chlorprothixene in man.* *Experientia* 1975;31:557-8.
- 535 Radtke RA. *Pharmacokinetics of levetiracetam.* *Epilepsia* 2001;42(Suppl 4):24-7.
- 536 Rao VA, Bishop M, Coppen A. *Clinical state, plasma levels of haloperidol and prolactin: a correlation study in chronic schizophrenia.* *Br J Psychiatry* 1980;137:518-21.
- 537 Rasmussen BB, Brøsen K. *Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?* *Ther Drug Monit* 2000;22:143-54.
- 538 Rasmussen PV, Jensen TS, Sindrup SH, et al. *TDM-based imipramine treatment in neuropathic pain.* *Ther Drug Monit* 2004;26:352-60.

- 539 Rauschenbach R, Gieschen H, Husemann M, et al. *Stable expression of human cytochrome P450 3A4 in V79 cells and its application for metabolic profiling of ergot derivatives.* Eur J Pharmacol 1995;293:183-90.
- 540 Ravva P, Gastonguay MR, Tensfeldt TG, et al. *Population pharmacokinetic analysis of varenicline in adult smokers.* Br J Clin Pharmacol 2009;68:669-81.
- 541 Rees JA. *Clinical interpretation of pharmacokinetic data on dothiepine hydrochloride (Dosulepin, Prothiaden).* J Int Med Res 1981;9:98-102.
- 542 Regenthal R, Krueger M, Koeppel C, et al. *Drug levels: therapeutic and toxic serum/plasma concentrations of common drugs.* J Clin Monit Comput 1999;15:529-44.
- 543 Reimold M, Solbach C, Noda S, et al. *Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol.* Psychopharmacology (Berl) 2007;190:241-9.
- 544 Reis M, Aamo T, Ahlner J, et al. *Reference concentrations of antidepressants. A compilation of post-mortem and therapeutic levels.* J Analyt Toxicol 2007;31:254-64.
- 545 Reis M, Aamo T, Spigset O, et al. *Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database.* Ther Drug Monit 2009;31:42-56.
- 546 Reis M, Åberg-Wistedt A, Ågren H, et al. *Compliance with SSRI medication during 6 months of treatment for major depression: an evaluation by determination of repeated serum drug concentrations.* J Affect Disorders 2004;82:443-6.
- 547 Reis M, Akerblad AC, Ekselius L, et al. *Partial compliance as determined from plasma levels of sertraline and its metabolite in depressed patients in primary care.* J Clin Psychopharmacol 2010;30:746-8.
- 548 Reis M, Chermá MD, Carlsson B, et al. *On behalf of the task force for TDM of escitalopram in Sweden. Therapeutic drug monitoring of escitalopram in an outpatient setting.* Ther Drug Monit 2007;29:758-66.
- 549 Reis M, Lundmark J, Bengtsson F. *Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992-1997.* Ther Drug Monit 2003;25:183-91.
- 550 Reis M, Lundmark J, Björk H, et al. *Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting.* Ther Drug Monit 2002;24:545-53.
- 551 Reis M, Olsson G, Carlsson B, et al. *Serum levels of citalopram and its main metabolites in adolescent patients treated in a naturalistic clinical setting.* J Clin Psychopharmacol 2002;22:406-13.
- 552 Reis M, Prochazka J, Sitsen A, et al. *Inter- and intraindividual pharmacokinetic variations of mirtazapine and its N-demethyl metabolite in patients treated for major depressive disorder: a 6-month therapeutic drug monitoring study.* Ther Drug Monit 2005;27:469-77.
- 553 Remington G, Mamo D, Labelle A, et al. *A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.* Am J Psychiatry 2006;163:396-401.
- 554 Renwick AB, Mistry H, Ball SE, et al. *Metabolism of Zaleplon by human hepatic microsomal cytochrome P450 isoforms.* Xenobiotica 1998;28:337-48.
- 555 Riant P, Urien S, Albengres E, et al. *Effects of the binding of imipramine to erythrocytes and plasma proteins on its transport through the rat blood-brain barrier.* J Neurochem 1988;51:421-5.
- 556 Richens A, Banfield CR, Salfi M, et al. *Single and multiple dose pharmacokinetics of felbamate in the elderly.* Br J Clin Pharmacol 1997;44:129-34.
- 557 Riedel M, Schwarz MJ, Strassnig M, et al. *Risperidone plasma levels, clinical response and side-effects.* Eur Arch Psychiatry Clin Neurosci 2005;255:261-8.
- 558 Rivas N, Buelga DS, Elger CE, et al. *Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy.* Ther Drug Monit 2008;30:483-9.
- 559 Rivera-Calimlim L, Castañeda L, Lasagna L. *Effects of mode of management on plasma chlorpromazine in psychiatric patients.* Clin Pharmacol Ther 1973;14:978-86.
- 560 Roberts RL, Joyce PR, Mulder RT, et al. *A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression.* Pharmacogenomics J 2002;2:191-6.
- 561 Robertson P Jr, Hellriegel ET. *Clinical pharmacokinetic profile of modafinil.* Clin Pharmacokinet 2003;42:123-37.
- 562 Rochat B, Kosel M, Boss G, et al. *Stereoselective biotransformation of the selective serotonin reuptake inhibitor, citalopram, and its demethylated metabolites by monoamine oxidases in human liver.* Biochem Pharmacol 1998;56:15-23.
- 563 Rogers SL, Friedhoff LT. *The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group.* Dementia 1996;7:293-303.
- 564 Roman M, Kronstrand R, Lindstedt D, et al. *Quantitation of seven low-dosage antipsychotic drugs in human postmortem blood using LC-MS-MS.* J Anal Toxicol 2008;32:147-55.
- 565 Ronfeld RA, Tremaine LM, Wilner KD. *Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers.* Clin Pharmacokinet 1997;32(Suppl 1):22-30.
- 566 Rosenzweig P, Canal M, Patat A, et al. *A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers.* Hum Psychopharmacol 2002;17:1-13.
- 567 Rotzinger S, Fang J, Baker GB. *Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources.* Drug Metab Dispos 1998;26:572-5.
- 568 Rougemont M, Ulrich S, Hiemke C, et al. *French summaries of product characteristics: content in relation to therapeutic monitoring of psychotropic drugs.* Fundam Clin Pharmacol 2010;24:377-84.
- 569 Rudorfer V, Potter WZ. *The role of metabolites of antidepressants.* J Clin Psychiatry 1998;59:13-20.

- sants in the treatment of depression. *CNS Drugs* 1997;7:273-312.
- 570 Ruottinen HM, Rinne UK. *Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients.* *Clin Neuropharmacol* 1996;19:222-33.
- 571 Sachse J, Härtter S, Hiemke C. *Automated determination of ziprasidone by HPLC with column switching and spectrophotometric detection.* *Ther Drug Monit* 2005;27:158-62.
- 572 Sachse J, Härtter S, Weigmann H, et al. *Automated determination of amisulpride by liquid chromatography with column switching and spectrophotometric detection.* *J Chromatogr B Analyt Technol Biomed Life Sci* 2003;784:405-10.
- 573 Sachse J, Köller J, Härtter S, et al. *Automated analysis of quetiapine and other antipsychotic drugs in human blood by high performance-liquid chromatography with column-switching and spectrophotometric detection.* *J Chromatogr B Analyt Technol Biomed Life Sci* 2006;830:342-8.
- 574 Sagar KA, Smyth MR. *Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection.* *Analyst* 2000;125:439-45.
- 575 Sage JL, Mark MH. *Pharmacokinetics of continuous-release carbidopa/levodopa.* *Clin Neuropharmacol* 1994;17(Suppl 2):1-6.
- 576 Sainati SM, Hubbard JW, Chi E, et al. *Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic.* *J Clin Pharmacol* 1995;35:713-20.
- 577 Saint-Marcoux F, Sauvage FL, Marquet P. *Current role of LC-MS in therapeutic drug monitoring.* *Anal Bioanal Chem* 2007;388:1327-49.
- 578 Saivin S, Hulot T, Chabac S, et al. *Clinical pharmacokinetics of acamprosate.* *Clin Pharmacokinet* 1998;35:331-45.
- 579 Sajatovic M, Velligan DI, Weiden PJ, et al. *Measurement of psychiatric treatment adherence.* *J Psychosom Res* 2010;69:591-9.
- 580 Salazar DE, Frackiewicz EJ, Dockens R, et al. *Pharmacokinetics and tolerability of buspirone during oral administration to children and adolescents with anxiety disorder and normal healthy adults.* *J Clin Pharmacol* 2001;41:1351-8.
- 581 Sallee FR, Pollock BG, Stiller RL, et al. *Pharmacokinetics of pimozide in adults and children with Tourette's syndrome.* *J Clin Pharmacol* 1987;27:776-81.
- 582 Sartorius N, Baghai TC, Baldwin DS, et al. *Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence.* *Int J Neuropsychopharmacol* 2007;10(Suppl 1):S1-207.
- 583 Sauer JM, Ring BJ, Witcher JW. *Clinical Pharmacokinetics of atomoxetine.* *Clin Pharmacokinet* 2005;44:571-90.
- 584 Sauvage FL, Gaulier JM, Lachâtre G, et al. *Pitfalls and prevention strategies for liquid chromatography-tandem mass spectrometry in the selected reaction-monitoring mode for drug analysis.* *Clin Chem* 2008;54:1519-27.
- 585 Schulberg HC, Katon W, Simon GE, et al. *Treating major depression in primary care practice: an update of the Agency for Health Care Policy and Research Practice Guidelines.* *Arch Gen Psychiatry* 1998;55:1121-7.
- 586 Schulz M, Schmoldt A. *Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics.* *Pharmazie* 2003;58:447-74.
- 587 Schwarzenbach F, Netillard C, Demoly P, et al. *Antidepressant response and fluvoxamine plasma concentrations: a pilot study.* *Pharm World Sci* 2003;25:27-9.
- 588 Scordo MG, Spina E, Dahl ML, et al. *Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.* *Basic Clin Pharmacol Toxicol* 2005;97:296-301.
- 589 Seiler W, Wetzel H, Hillert A, et al. *Pharmacokinetics and bioavailability of benperidol in schizophrenic patients after intravenous and two different kinds of oral application.* *Psychopharmacology (Berl)* 1994;116:457-63.
- 590 Service JA, Waring WS. *QT Prolongation and delayed atrioventricular conduction caused by acute ingestion of trazodone.* *Clin Toxicol (Phila)* 2008;46:71-3.
- 591 Shams M, Hiemke C, Härtter S. *Therapeutic drug monitoring of antidepressant mirtazapine and its N-demethylated metabolite in human serum.* *Ther Drug Monit* 2004;26:78-84.
- 592 Shams ME, Arneth B, Hiemke C, et al. *CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.* *J Clin Pharm Ther* 2006;31:493-502.
- 593 Sharma S, Joshi S, Chadda RK. *Therapeutic drug monitoring of lithium in patients with bipolar affective disorder: experiences from a tertiary care hospital in India.* *Am J Ther* 2009;16:393-7.
- 594 Shin JG, Soukova N, Flockart DA. *Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: Preferential inhibition of CYP2D6.* *Drug Metab Dispos* 1999;27:1078-84.
- 595 Shinderman M, Maxwell S, Brawand-Amey M, et al. *Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses.* *Drug Alcohol Depend* 2003;69:205-11.
- 596 Shiraga T, Kaneko H, Iwasaki K, et al. *Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes.* *Xenobiotica* 1999;29:217-29.
- 597 Shua-Haim J, Smith J, Picard F, et al. *Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study.* *Clin Drug Investig* 2008;28:361-74.
- 598 Sidhu J, Priskorn M, Poulsen M, et al. *Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in human.* *Chirality* 1997;9:686-92.
- 599 Siva N. *Tackling the booming trade in counterfeit drugs.* *Lancet* 2010;376:1725-6.
- 600 Skinner MH, Kuan HY, Skerjanec A, et al. *Effect of age on*

- the pharmacokinetics of duloxetine in women. *Br J Clin Pharmacol* 2004;57:54-61.
- 601 Skogh E, Bengtsson F, Nordin C. Could discontinuing smoking be hazardous for patients administered clozapine medication? A case report. *Ther Drug Monit* 1999;21:580-2.
- 602 Skogh E, Reis M, Dahl ML, et al. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. *Ther Drug Monit* 2002;24:518-26.
- 603 Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. *Seroquel study group. Arch Gen Psychiatry* 1997;54:549-57.
- 604 Smith RB, Kroboth PD, Vanderlugt JT, et al. Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. *Psychopharmacology (Berl)* 1984;84:452-6.
- 605 Smith SW. Chiral toxicology: it's the same thing... only different. *Toxicol Sci* 2009;110:4-30.
- 606 Snoeck E, Van Peer A, Sack M, et al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. *Psychopharmacology (Berl)* 1995;122:223-9.
- 607 Sogaard B, Mengel H, Rao N, et al. The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. *J Clin Pharmacol* 2005;45:1400-6.
- 608 Soldin P, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. *Clin Pharmacokinet* 2009;48:143-57.
- 609 Someya T, Muratake T, Hirokane G, et al. Interindividual variation in bromperidol metabolism and relationship to therapeutic effects. *J Clin Psychopharmacol* 2000;20:175-80.
- 610 Søndergaard Khinchi M, Nielsen KA, Dahl M, et al. Lamotrigine therapeutic thresholds. *Seizure* 2008;17:391-5.
- 611 Soni SD. Fluspirilene in the treatment of non-hospitalized schizophrenic patients. *Curr Med Res Opin* 1977;4:645-9.
- 612 Sparshatt A, Taylor D, Patel MX, et al. A systematic review of aripiprazole-dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. *J Clin Psychiatry* 2010;71:1447-56.
- 613 Sparshatt A, Taylor D, Patel MX, et al. Amisulpride. Dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring. *Acta Psychiatr Scand* 2009;120:416-28.
- 614 Spencer TJ, Biederman J, Ciccone PE, et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. *Am J Psychiatry* 2006;163:387-95.
- 615 Spencer TJ, Bonab AA, Dougherty DD, et al. A PET study examining pharmacokinetics and dopamine transporter occupancy of two long-acting formulations of methylphenidate in adults. *Int J Mol Med* 2010;25:261-5.
- 616 Spigset O, Hägg S, Stegmayr B, et al. Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis. *Eur J Clin Pharmacol* 2000;59:699-703.
- 617 Spina E, Avenoso A, Facciola G, et al. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. *Psychopharmacology (Berl)* 2001;153:238-43.
- 618 Spina E, Birgersson C, von Bahr Ö, et al. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes. *Clin Pharmacol Ther* 1984;36:677-82.
- 619 Sproule BA, Hardy BG, Shulman KI. Differential pharmacokinetics of lithium in elderly patients. *Drugs Aging* 2000;16:165-77.
- 620 Stassen HH, Angheliescu IG, Angst J, et al. Predicting response to psychopharmacological treatment. Survey of recent results. *Pharmacopsychiatry* 2011;44:263-72.
- 621 Stassen HH, Angst J, Hell D, et al. Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. *J Clin Psychiatry* 2007;68:1195-205.
- 622 Stead AH, Moffat AC. A collection of therapeutic, toxic and fatal blood drug concentrations in man. *Hum Exp Toxicol* 1983;3:437-64.
- 623 Steimer W. Pharmacogenetics and psychoactive drug therapy: ready for the patient? *Ther Drug Monit* 2010;32:381-6.
- 624 Steimer W, Potter JM. Pharmacogenetic screening and therapeutic drugs. *Clin Chim Acta* 2002;315:137-55.
- 625 Steimer W, Zöpf K, von Amelunxen S, et al. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. *Clin Chem* 2005;51:376-85.
- 626 Stieffenhofer V, Hiemke C. Pharmacogenetics, therapeutic drug monitoring and non compliance. *Ther Umsch* 2010;67:309-15.
- 627 Stieffenhofer V, Saglam H, Schmidtmann I, et al. Clozapine plasma level monitoring for prediction of rehospitalization schizophrenic outpatients. *Pharmacopsychiatry* 2011;44:55-9.
- 628 Stock B, Spittler G. Metabolism of antiparkinson drugs. An example of competitive hydroxylation. *Arzneimittelforschung* 1979;29:610-5.
- 629 Störmer E, Brockmüller J, Roots I, et al. Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug in vitro. *Psychopharmacology (Berl)* 2000;151:312-20.
- 630 Störmer E, von Moltke LL, Shader RI, et al. Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. *Drug Metab Dispos* 2000;28:1168-75.
- 631 Suhara T, Takano A, Sudo Y, et al. High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. *Arch Gen Psychiatry* 2003;60:386-91.

- ⁶³² Sutfin TA, Perini GI, Molnar G, et al. *Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients.* J Clin Psychopharmacol 1988;8:48-53.
- ⁶³³ Suzuki A, Otani K, Ishida M, et al. *Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine.* Ther Drug Monit 1997;19:261-4.
- ⁶³⁴ Suzuki Y, Fukui N, Sawamura K, et al. *Concentration-response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression.* J Clin Psychopharmacol 2008;28:325-8.
- ⁶³⁵ Svrbely JR, Speicher CE. *The importance of request and report forms in the interpretation of therapeutic drug monitoring data.* Ther Drug Monit 1980;2:211-6.
- ⁶³⁶ Sweet RA, Pollock BG, Kirshner M, et al. *Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression.* J Clin Pharmacol 1995;35:876-84.
- ⁶³⁷ Sweet RA, Pollock BG, Mulsant BH, et al. *Pharmacologic profile of perphenazine's metabolites.* J Clin Psychopharmacol 2000;20:181-7.
- ⁶³⁸ Szegedi A, Jansen WT, van Willigenburg AP, et al. *Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients.* J Clin Psychiatry 2009;70:344-53.
- ⁶³⁹ Takano A, Suhara T, Ichimiya T, et al. *Time course of in vivo 5-HTT transporter occupancy by fluvoxamine.* J Clin Psychopharmacol 2006;26:188-91.
- ⁶⁴⁰ Takano A, Suzuki K, Kosaka J, et al. *A dose-finding study of duloxetine based on serotonin transporter occupancy.* Psychopharmacology 2006;185:395-9.
- ⁶⁴¹ Tan L, Yu JT, Sun YP, et al. *The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients.* Clin Neurol Neurosurg 2010;112:320-3.
- ⁶⁴² Tanaka O, Kondo T, Otani K, et al. *Single oral dose kinetics of zotepine and its relationship to prolactin response and side effects.* Ther Drug Monit 1998;20:117-9.
- ⁶⁴³ Tanaka E, Kurata N, Yasuhara H. *How useful is the "cocktail approach" for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?* J Clin Pharm Ther 2003;28:157-65.
- ⁶⁴⁴ Tasker TCG, Kaye CM, Zussman BD, et al. *Paroxetine plasma levels: lack of correlation with efficacy or adverse events.* Acta Psychiatr Scand 1989;80(Suppl 350):152-5.
- ⁶⁴⁵ Tateishi T, Watanabe M, Kumai T, et al. *CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes.* Life Sci 2000;67:2913-20.
- ⁶⁴⁶ Taylor D. *Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety.* Acta Psychiatr Scand 2008;118:434-42.
- ⁶⁴⁷ Taylor D. *Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review.* Br J Psychiatry Suppl 2009;52:S13-9.
- ⁶⁴⁸ Thanacoody RH, Daly AK, Reilly JG, et al. *Factors affecting drug concentrations and QT interval during thioridazine therapy.* Clin Pharmacol Ther 2007;82:555-65.
- ⁶⁴⁹ The Scottish Schizophrenia Research Group. *The Scottish first episode Schizophrenia study II. Treatment: pimozide versus flupenthixol.* Br J Psychiatry 1987;150:334-8.
- ⁶⁵⁰ Thieme D, Rolf B, Sachs H, et al. *Correlation of inter-individual variations of amitriptyline metabolism examined in hairs with CYP2C19 and CYP2D6 polymorphisms.* Int J Legal Med 2008;122:149-55.
- ⁶⁵¹ Timmer CJ, Sitsen JM, Delbressine LP. *Clinical pharmacokinetics of mirtazapine.* Clin Pharmacokinet 2000;38:461-74.
- ⁶⁵² Tiseo PJ, Rogers SL, Friedhoff LT. *Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration.* Br J Clin Pharmacol 1998;46(Suppl 1):13-8.
- ⁶⁵³ Titier K, Canal M, Déridet E, et al. *Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice.* Toxicol Appl Pharmacol 2004;199:52-60.
- ⁶⁵⁴ Toennes SW, Maurer HH. *Microsoft Excel in pharmacokinetics. An easy way to solve kinetic problems in clinical toxicology, legal medicine or doping control.* In: Sachs H, Bernhard W, Jeger A, editors. *Proceedings of the 34th International TIAFT Meeting, Interlaken, 11-15 August 1996.* Leipzig: Molina 1997, pp. 201-204.
- ⁶⁵⁵ Tokairin T, Fukasawa T, Yasui-Furukori N, et al. *Inhibition of the metabolism of brotizolam by erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in brotizolam metabolism.* Br J Clin Pharmacol 2005;60:172-5.
- ⁶⁵⁶ Tokunaga H, Kudo K, Imamura T, et al. *Plasma concentrations of antipsychotic drugs in psychiatric inpatients.* Nippon Hoigaku Zasshi 1997;51:417-22.
- ⁶⁵⁷ Tompson DJ, Vearer D. *Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson's disease.* Clin Ther 2007;29:2654-66.
- ⁶⁵⁸ Topiwala A, Fazel S. *The pharmacological management of violence in schizophrenia: a structured review.* Expert Rev Neurother 2011;11:53-63.
- ⁶⁵⁹ Tornio A, Neuvonen PJ, Backman JT. *The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone.* Eur J Clin Pharmacol 2006;62:645-51.
- ⁶⁶⁰ Touw DJ, Neef C, Thomson AH, et al. *Cost-effectiveness of therapeutic drug monitoring: a systematic review.* Ther Drug Monit 2005;27:10-7.
- ⁶⁶¹ Trivedi MH, Rush AJ, Gaynes BN, et al. *Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurement-based care.* Neuropsychopharmacol 2007;32:2479-89.
- ⁶⁶² Tsai MH, Lin KM, Hsiao MC, et al. *Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.* Pharmacogenomics 2010;11:537-46.

- ⁶⁶³ Tuerck D, Wang Y, Maboudian M, et al. *Similar bioavailability of dexamethylphenidate extended (bimodal) release, dexamethylphenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man.* Int J Clin Pharmacol Ther 2007;45:662-8.
- ⁶⁶⁴ Turbott J, Norman TR, Burrows GD, et al. *Pharmacokinetics of nortriptyline in elderly volunteers.* Commun Psychopharmacol 1980;4:225-31.
- ⁶⁶⁵ Turpeinen M, Koivuviita N, Tolonen A, et al. *Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites.* Br J Clin Pharmacol 2007;64:165-73.
- ⁶⁶⁶ Uchida H, Mamo DC, Mulsant BH, et al. *Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms.* J Clin Psychiatry 2009;70:397-405.
- ⁶⁶⁷ Uhr M, Steckler T, Yassouridis A, et al. *Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption.* Neuropsychopharmacology 2000;22:380-7.
- ⁶⁶⁸ Uhr M, Tontsch A, Namendorf C, et al. *Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression.* Neuron 2008;57:203-39.
- ⁶⁶⁹ Ujiié Y, Fukasawa T, Yasui-Furukori N, et al. *Rifampicin markedly decreases plasma concentration and hypnotic effect of brotizolam.* Ther Drug Monit 2006;28:299-302.
- ⁶⁷⁰ Ulrich S, Baumann B, Wolf R, et al. *Therapeutic drug monitoring of clozapine and relapse—a retrospective study of routine clinical data.* Int J Clin Pharmacol Ther 2003;41 3-13.
- ⁶⁷¹ Ulrich S, Hiemke C, Laux G, et al. *TDM group of the Arbeitsgemeinschaft Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). Value and actuality of the prescription information for therapeutic drug monitoring of psychopharmaceuticals: a comparison with the medico-scientific evidence.* Pharmacopsychiatry 2007;40:121-7.
- ⁶⁷² Ulrich S, Läuter J. *Comprehensive survey of the relationship between serum concentration and therapeutic effect of amitriptyline in depression.* Clin Pharmacokinet 2002;41:853-76.
- ⁶⁷³ Ulrich S, Sandmann U, Genz A. *Serum concentrations of haloperidol pyridinium metabolites and the relationship with tardive dyskinesia and parkinsonism: a cross-section study in psychiatric patients.* Pharmacopsychiatry 2005;38:171-7.
- ⁶⁷⁴ Ulrich S, Wurthmann C, Brosz M, et al. *The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia.* Clin Pharmacokinet 1998;34:227-63.
- ⁶⁷⁵ Valdes R Jr, Payne DA, Linder MW, editors. *Laboratory medicine practice guidelines and recommendations for laboratory analysis and application of pharmacogenetics to clinical practice.* Washington, DC: National Academy of Clinical Biochemistry 2010.
- ⁶⁷⁶ Van der Weide J, Steijns LS, van Weelden MJ. *The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement.* Pharmacogenetics 2003;13:169-72.
- ⁶⁷⁷ Van der Weide J, van Baalen-Benedek EH, Kootstra-Ros JE. *Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype.* Ther Drug Monit 2005;27:478-83.
- ⁶⁷⁸ Van der Zwaag C, McGee M, McEvoy JP, et al. *Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges.* Am J Psychiatry 1996;153:1579-84.
- ⁶⁷⁹ Van Gorp F, Whyte IM, Isbister GK. *Clinical and ECG effects of Escitalopram overdose.* Ann Emerg Med 2009;54:4-408.
- ⁶⁸⁰ Van Putten T, Marder SR, Wirshing WC, et al. *Neuroleptic plasma levels.* Schizophr Bull 1991;17:197-216.
- ⁶⁸¹ Varsaldi F, Miglio G, Scordo MG, et al. *Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients.* Eur J Clin Pharmacol 2006;62:721-6.
- ⁶⁸² Vasudev K, Das S, Goswami U, et al. *Pharmacokinetics of valproic acid in patients with bipolar disorder.* J Psychopharmacol 2001;15:187-90.
- ⁶⁸³ Vasudev K, Goswami U, Kohli K. *Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder.* Psychopharmacology (Berl) 2000;150:15-23.
- ⁶⁸⁴ Veefkind AH, Haffmans PMJ, Hoencamp E. *Venlafaxine serum levels and CYP2D6 genotype.* Ther Drug Monit 2000;22:202-8.
- ⁶⁸⁵ Velligan DI, Lam YW, Glahn DC, et al. *Defining and assessing adherence to oral antipsychotics: a review of the literature.* Schizophr Bull 2006;32:724-42.
- ⁶⁸⁶ Venkatakrisnan K, Culm KE, Ehrenberg BL, et al. *Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy volunteers.* J Clin Pharmacol 2005;45:529-37.
- ⁶⁸⁷ Venkatakrisnan K, von Moltke LL, Greenblatt DJ. *Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs.* J Clin Pharmacol 1999;39:567-77.
- ⁶⁸⁸ Vernaleken I, Fellows C, Janouschek H, et al. *Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone).* J Clin Psychopharmacol 2008;28:608-17.
- ⁶⁸⁹ Vernaleken I, Janouschek H, Raptis M, et al. *Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas.* Int J Neuropsychopharmacol 2010;13:951-60.
- ⁶⁹⁰ Vernaleken I, Siessmeier T, Buchholz HG, et al. *High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia.* Int J Neuropsychopharmacol 2004;7:421-30.
- ⁶⁹¹ Ververs FF, Voorbij HA, Zwarts P, et al. *Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy.* Clin Pharmacokinet 2009;48:677-83.
- ⁶⁹² Viala A, Ba B, Durand A, et al. *Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphen-*

- azine decanoate. *Psychopharmacology* (Berl) 1988;94:293-7.
- ⁶⁹³ Vine W, Bowers LD. *Cyclosporine: structure, pharmacokinetics, and therapeutic drug monitoring*. *Crit Rev Clin Lab Sci* 1987;25:275-311.
- ⁶⁹⁴ Viola MS, Bercellini MA, Saidon P, et al. *Pharmacokinetic variability of oxcarbazepine in epileptic patients*. *Medicina* (B Aires) 2000;60:914-8.
- ⁶⁹⁵ Vogel F, Gansmüller R, Leiblein T, et al. *The use of ziprasidone in clinical practice: Analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey*. *Eur Psychiatry* 2009;24:143-8.
- ⁶⁹⁶ Voineskos AN, Wilson AA, Boovariwala A, et al. *Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography*. *Psychopharmacology* (Berl) 2007;193:539-45.
- ⁶⁹⁷ Von Moltke LL, Greenblatt DJ, Giancarlo GM, et al. *Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram*. *Drug Metab Dispos* 2001;29:1102-9.
- ⁶⁹⁸ Von Moltke LL, Greenblatt DJ, Granda BW, et al. *Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations*. *Br J Clin Pharmacol* 1999;48:89-97.
- ⁶⁹⁹ Vormfelde SV, Bitsch A, Meineke I, et al. *Non-response to maprotiline caused by ultra-rapid metabolism that is different from CYP2D6?* *Eur J Clin Pharmacol* 1997;52:387-90.
- ⁷⁰⁰ Vuille F, Amey M, Baumann P. *Use of plasma level monitoring of antidepressants in clinical practice. Towards an analysis of clinical utility*. *Pharmacopsychiatry* 1991;24:190-5.
- ⁷⁰¹ Waade RB, Christensen H, Rudberg I, et al. *Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole*. *Ther Drug Monit* 2009;31:233-8.
- ⁷⁰² Waldschmitt C, Vogel F, Maurer C, et al. *Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching*. *Ther Drug Monit* 2007;29:767-72.
- ⁷⁰³ Waldschmitt C, Vogel F, Pfuhlmann B, et al. *Duloxetine serum concentrations and clinical effects. Data from a therapeutic drug monitoring (TDM) survey*. *Pharmacopsychiatry* 2009;42:189-93.
- ⁷⁰⁴ Wan J, Xia H, He N, et al. *The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype*. *Br J Clin Pharmacol* 1996;42:471-4.
- ⁷⁰⁵ Wang JH, Liu ZQ, Wang W, et al. *Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19*. *Clin Pharmacol Ther* 2001;70:42-7.
- ⁷⁰⁶ Ward E, Musa MN, Bailey LG. *Clinical pharmacokinetics of lithium*. *J Clin Pharmacol* 1994;34:280-5.
- ⁷⁰⁷ Weber J, McCormack PL. *Asenapine*. *CNS Drugs* 2009;23:781-92.
- ⁷⁰⁸ Weiden PJ, Kozma C, Grogg A, et al. *Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia*. *Psychiatr Serv* 2004;55:886-91.
- ⁷⁰⁹ Weigmann H, Bierbrauer J, Härtter S, et al. *Automated determination of clozapine and major metabolites in serum and urine*. *Ther Drug Monit* 1997;19:480-8.
- ⁷¹⁰ Weigmann H, Härtter S, Hiemke C. *Automated determination of clomipramine and its major metabolites in human and rat serum by high-performance liquid chromatography with on-line column-switching*. *J Chromatogr B Biomed Sci Appl* 1998;710:227-33.
- ⁷¹¹ Weigmann H, Härtter S, Maehrlin S, et al. *Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column-switching high-performance liquid chromatography*. *J Chromatogr B Biomed Sci Appl* 2001;759:63-71.
- ⁷¹² Weiss U, Marksteiner J, Kemmler G, et al. *Effects of age and sex on olanzapine plasma concentrations*. *J Clin Psychopharmacol* 2005;25:570-4.
- ⁷¹³ Wen B, Ma L, Zhu M. *Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s*. *Chem Biol Interact* 2008;173:59-67.
- ⁷¹⁴ Wen B, Zhou M. *Metabolic activation of the phenothiazine antipsychotics chlorpromazine and thioridazine to electrophilic iminoquinone species in human liver microsomes and recombinant P450s*. *Chem Biol Interact* 2009;181:220-6.
- ⁷¹⁵ White NC, Litovitz T, Clancy C. *Suicidal antidepressant overdoses: a comparative analysis by antidepressant type*. *J Med Toxicol* 2008;4:238-50.
- ⁷¹⁶ Wienkers LC, Allievi C, Hauer MJ, et al. *Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes*. *Drug Metab Dispos* 1999;27:1334-40.
- ⁷¹⁷ Wiesel FA, Alfredsson G, Ehrnebo M, et al. *The pharmacokinetics of intravenous and oral sulphiride in healthy human subjects*. *Eur J Clin Pharmacol* 1980;17:385-91.
- ⁷¹⁸ Wille SM, Cooreman SG, Neels HM, et al. *Relevant issues in the monitoring and the toxicology of antidepressants*. *Crit Rev Clin Lab Sci* 2008;45:25-89.
- ⁷¹⁹ Willmore LJ, Abelson MB, Ben-Menachem E, et al. *Vigabatrin: 2008 update*. *Epilepsia* 2009;50:163-73.
- ⁷²⁰ Wilson JF. *Survey of reference ranges and clinical measurements for psychoactive drugs in serum*. *Ther Drug Monit* 2003;25:243-7.
- ⁷²¹ Wilting I, Heerdink ER, Mersch PP, et al. *Association between lithium serum level, mood state, and patient-reported adverse drug reactions during long-term lithium treatment: a naturalistic follow-up study*. *Bipolar Disord* 2009;11:434-40.
- ⁷²² Wincor MZ, Munjack DJ, Palmer R. *Alprazolam levels and response in panic disorder: preliminary results*. *J Clin Psychopharmacol* 1991;11:48-51.
- ⁷²³ Winter HR, Earley WR, Hamer-Maansson JE, et al. *Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, Norquetiapine, and other quetiapine metabo-*

- lites in pediatric and adult patients with psychotic disorders.* J Child Adolesc Psychopharmacol 2008;18:81-98.
- ⁷²⁴ Wójcikowski J, Boksa J, Daniel WA. *Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver. A comparison with other phenothiazines.* Biochem Pharmacol 2010;80:1252-9.
- ⁷²⁵ Wójcikowski J, Daniel WA. *Perazine at therapeutic drug concentrations inhibits human cytochrome P450 isoenzyme 1A2 (CYP1A2) and caffeine metabolism-an in vitro study.* Pharmacol Rep 2009;61:851-8.
- ⁷²⁶ Wójcikowski J, Pichard-Garcia L, Maurel P, et al. *Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine.* Br J Pharmacol 2003;138:1465-74.
- ⁷²⁷ Wolff K, Hay AW, Rasitrick D, et al. *Steady-state pharmacokinetics of methadone in opioid addicts.* Eur J Clin Pharmacol 1993;44:189-94.
- ⁷²⁸ Wong SL, Granneman GR. *Modeling of sertindole pharmacokinetic dispositions in healthy volunteers in short term dose-escalation studies.* J Pharmaceut Sci 1998;87:1629-31.
- ⁷²⁹ Wong SL, Menacherry S, Mulford D, et al. *Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function.* Eur J Clin Pharmacol 1997;52:223-7.
- ⁷³⁰ Wright CE, Sisson TL, Ichhpurani AK, et al. *Steady-state pharmacokinetic properties of pramipexole in healthy volunteers.* J Clin Pharmacol 1997;37:520-5.
- ⁷³¹ Wynalda MA, Wienkers LC. *Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen.* Drug Metab Dispos 1997;25:1211-4.
- ⁷³² Xiang Q, Zhao X, Zhou Y, et al. *Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety.* J Clin Pharmacol 2010;50:659-66.
- ⁷³³ Xu P, Li HD, Zhang BK, et al. *Pharmacokinetics and tolerability of modafinil tablets in Chinese subjects.* J Clin Pharm Ther 2008;33:429-37.
- ⁷³⁴ Yao C, Raoufinia A, Gold M, et al. *Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects.* J Clin Pharmacol 2005;45:519-28.
- ⁷³⁵ Yasui-Furukori N, Kondo T, Ishida M, et al. *The characteristics of side-effects of bromperidol in schizophrenic patients.* Psychiatry Clin Neurosci 2002;56:103-6.
- ⁷³⁶ Yasui-Furukori N, Saito M, Nakagami T, et al. *Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study.* Prog Neuropsychopharmacol Biol Psychiatry 2006;30:286-91.
- ⁷³⁷ Yasui-Furukori N, Saito M, Nakagami T, et al. *Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients.* J Psychopharmacol 2010;24:987-94.
- ⁷³⁸ Yeung PK, Hubbard JW, Korschinski ED, et al. *Pharmacokinetics of chlorpromazine and key metabolites.* Eur J Clin Pharmacol 1993;45:563-9.
- ⁷³⁹ Yin OQ, Wing YK, Cheung Y, et al. *Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients.* J Clin Psychopharmacol 2006;26:367-72.
- ⁷⁴⁰ Yu DK, Dimmitt DC, Lanman RC, et al. *Pharmacokinetics of dothiepin in humans: a single dose dose-proportionality study.* J Pharm Sci 1986;75:582-5.
- ⁷⁴¹ Zernig G, Hiemke C, Havemann-Reinecke U, et al. *Empfehlungen für die gutachterliche Bewertung von Medikamentenspiegeln in der Psychiatrie im gerichtsanhängigen Schadensfall.* Psychopharmakotherapie 2009;16:57-64.
- ⁷⁴² Zernig G, Lechner T, Kramer-Reinstadler K, et al. *What the clinician still has to be reminded of.* Ther Drug Monit 2004;26:582.
- ⁷⁴³ Zernig G, Ng K, Hiemke C, et al. *Therapeutic drug monitoring-based clozapine dosing recommendations.* Ther Drug Monit 2007;29:130-1.
- ⁷⁴⁴ Zhao Q, Iyer GR, Verhaeghe T, et al. *Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.* J Clin Pharmacol 2002;42:428-36.
- ⁷⁴⁵ Zhou SF. *Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.* Clin Pharmacokinet 2009;48:689-723.
- ⁷⁴⁶ Zhou SF. *Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.* Clin Pharmacokinet 2009;48:761-804.
- ⁷⁴⁷ Zhou SF, Liu JP, Chowbay B. *Polymorphism of human cytochrome P450 enzymes and its clinical impact.* Drug Metab Rev 2009;41:89-295.
- ⁷⁴⁸ Zimmerman NP, Hickie IB, McGorry PD. *Guidelines for youth depression: time to incorporate new perspectives.* Med J Aust 2010;193:557.
- ⁷⁴⁹ Zullino DF, Delessert D, Eap CB, et al. *Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine.* Int Clin Psychopharmacol 2002;17:141-3.